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PGTandMe:  
SOCIAL NETWORKING-BASED 
GENETIC TESTING AND THE 
EVOLVING RESEARCH MODEL 
 
Valerie Gutmann Koch† 
 
 
ABSTRACT 
 
The opportunity to use extensive genetic data, personal information, 
and family medical history for research purposes may be naturally 
appealing to the personal genetic testing (PGT) industry, which is 
already coupling direct-to-consumer (DTC) products with social net-
working technologies, as well as to potential industry or institutional 
partners.  This article evaluates the transformation in research that the 
hybrid of PGT and social networking will bring about, and—
highlighting the challenges associated with a new paradigm of “pa-
tient-driven” genomic research—focuses on the consequences of 
shifting the structure, locus, timing, and scope of research through 
genetic crowd-sourcing.  This article also explores potential ethical, 
legal, and regulatory issues that arise from the 
hybrid between personal genomic research and online social network-
ing, particularly regarding informed consent, institutional review 
board (IRB) oversight, and ownership/intellectual property (IP) con-
siderations. 
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INTRODUCTION: BLOOD, SWEAT, TEARS . . . AND SPIT 
 
Lorenzo Odone’s struggle with adrenoleukodystrophy (ALD), a 
rare incurable genetic disorder that results in brain damage, failure of 
the adrenal glands and, eventually, death, was memorialized in the 
Oscar-nominated film Lorenzo’s Oil.  The 1992 movie tells the story 
of Lorenzo’s parents’ mission to find a cure on their own, after failing 
to find a doctor who could treat their son’s illness.1  They reviewed 
studies and experiments, questioned doctors, organized an interna-
tional symposium about ALD, and sought out a chemist to distill the 
oil that, in the movie, stopped the progression of Lorenzo’s disease.  
The moral of the story is that if the medical world fails to help us, we 
must help ourselves, even if it means contributing our own blood, 
sweat, and tears to find the treatments or cures we seek. 
Today, genetic technology holds the promise of better and more 
frequent treatments and cures.  It is also being used for more recrea-
tional purposes—allowing customers to glean personal health and 
ancestral data for informational and nonmedical reasons.  Most per-
  
 1 LORENZO’S OIL (1992); Roger Ebert, Lorenzo’s Oil, ROGEREBERT.COM 
(Jan. 15, 1993), 
http://rogerebert.suntimes.com/apps/pbcs.dll/article?AID=/19930115/REVIEWS/301
150303/1023.   
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sonal genome testing (PGT) kits require the consumer to send in a 
DNA sample—often a spit sample or cheek swab—which is analyzed 
by a U.S. government-certified laboratory.2  The company then noti-
fies the consumer of the results by telephone, mail, or, more recently, 
online.  Now that some PGT companies have coupled their direct-to-
consumer (DTC) products with social networking technologies,3 con-
sumers can communicate and share their information—including ex-
tensive personal information, genetic data, and family history—with 
others.  
The opportunity to use such a wealth of information for research 
purposes is naturally appealing to the PGT companies and their poten-
tial industry or institutional partners.  Sourcing research participants 
from social networking sites is often referred to as “crowd-sourcing” 
or “open-source research.”  PGT companies such as 23andMe have 
heralded the advantages of what they refer to as the “democratization 
of research,” or “patient-driven research.”4  Often referred to as “col-
laborative,” consumers/participants are purportedly involved in choos-
ing the focus of the research and contributing their own genetic and 
personal data.   
Genomic research arising out of PGT and social networking could 
produce a number of transformations in the model for clinical re-
search.  Recruitment and enrollment problems could be lessened as 
patient pools become larger and more diverse.  Data shortages or gaps 
could be eliminated as participants could share every aspect of their 
personal and genetic information.  Doubts about the validity of the 
results and uncertainty about conclusions could be reduced, as inves-
tigators could more easily reproduce each others’ research.5  The 
combination of DTC genomic testing services with online social net-
working promises the advancement of research across entire popula-
tions as well as for personalized medicine, or pharmacogenomics, 
  
 2 See CTRS. MEDICARE & MEDICAID SERVS., Clinical Laboratory Improve-
ment Amendments (CLIA), http://www.cms.gov/CLIA/ (last updated July 12, 2011). 
 3 Generally, online social networking involves sharing and communicating 
information over the internet.  Online communities provide a forum for people with 
similar interests, activities, or goals. 
 4 See, e.g., Rob Waters, Google-Backed 23andMe Seeks Parkinson’s Pa-
tients Spit (Update 1), BLOOMBERG (Mar. 12, 2009) (quoting Ann Wojcicki, who 
stated, “We also believe we are really democratizing research in a new way.”), 
http://www.bloomberg.com/apps/news?pid=newsarchive&refer=home&sid=akLbmqi
B1lSw. 
 5 One early example of patient-driven medical advances using social net-
working technology is Flu Wiki, which is used to generate epidemiological maps of 
illness outbreaks.  FLUWIKI, http://www.fluwiki.info/ (last visited Sept. 17, 2009). 
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shifting both the focus and locus of research and revealing challenges 
that are not addressed by our current regulatory framework.   
This article focuses on the potential ethical, legal, and regulatory 
issues that arise from bringing together personal genomic research and 
online social networking, and highlights the challenges associated 
with a new paradigm of “patient-driven” genomic research.  Part II 
includes a summary of the PGT/social networking products currently 
on the market—with respect to both the testing services available and 
the companies’ intentions to use data for research purposes.  Part III 
considers the evolving PGT/social networking hybrid for clinical re-
search.  Part IV discusses the implications of social networking-based 
genetic research in terms of shifting the structure, locus, timing, and 
scope of human subjects research.  Part V explores the implications 
this evolving research model may have on a number of ethical, legal, 
and policy dimensions related to informed consent and institutional 
review board (IRB) oversight.  Finally, Part VI addresses ownership 
and intellectual property (IP) considerations for the contributions or 
products of the techno-social hybrid of PGT and social networking. 
I.    PERSONAL GENOMIC TESTING: WHAT’S ON THE     
MARKET NOW? 
 
The market for PGT continues to expand, with a test to match the 
needs of almost any consumer.  There are services that provide genea-
logical information to fill in a family tree (e.g., deCODE Genetics or 
23andMe) and tests focused on disease and trait prediction (e.g., 
23andMe, Navigenics, Pathway Genomics, or Interleukin Genetics).  
There are tests based on single-nucleotide polymorphisms (SNPs) or 
specific genetic markers (e.g., 23andMe, Navigenics, or Pathway Ge-
nomics), and tests that conduct genome-wide scans (e.g., Knome).  
There are options for individuals who are concerned with privacy 
(e.g., Knome) as well as for those who want the opportunity to share 
and discuss their test results with others (e.g., 23andMe).  Some com-
panies require customers to sign “informed consent” forms prior to 
purchasing a service or participating in genetic research while others 
do not.  Some disclose the potential use of the data gleaned from their 
websites in future research—either by internal investigators or by 
those who have purchased rights to the databases of information—
while others currently have no intent to conduct any research at all.  
Each company’s offerings vary by price, services, and policies, and 
new companies and products seem to enter the market daily.  Al-
though Interleukin Genetics, Knome, Navigenics, deCODE Genetics, 
Pathway Genomics, TruGenetics, and 23andMe all provide some form 
of PGT service, not all of them intend to pursue research agendas util-
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izing the information to identify tests, diagnostics, or treatments.  
However, the collection of genomic data, often coupled with other 
personal information, renders a discussion of their services and poli-
cies useful.   
Knome (pronounced “know me”) is a private PGT company that 
interprets human genomes for pharmaceutical and clinical research-
ers.6  The company, founded in 2007, was the first of its kind to com-
mercially offer complete genomic sequencing.  To meet the needs of 
the research community, Knome established KnomeDISCOVERY to 
deliver data and analysis for complete human genome and exome se-
quencing.7  Unlike some of the other companies that offer social net-
working opportunities, Knome has emphasized privacy.8    
deCODE Genetics’ service provides disease-specific genetic tests, 
as well as a genealogy service.9  deCODE Genetics’ services include a 
full forty-seven disease and trait scan (including ancestry informa-
tion), a “Cardio” scan, and a “Cancer” scan.10  The conditions covered 
by deCODE Genetics’ complete scan, which captures over a million 
SNPs, include breast cancer, risk of heart attack, obesity, psoriasis, 
Alzheimer’s disease, asthma, eye color, and restless leg syndrome.11  
Results of the genetic analysis, performed in deCODE Genetics’ labo-
  
 6 FAQs, KNOME, http://knome.com/company/faqs/ (last visited Apr. 12, 
2011). In July 2011, scientists used Knome’s services to aid in the discovery of a 
mutation associated with an inherited form of Parkinson’s disease. Carles Vilariño-
Güell et al., VPS35 Mutations in Parkinson Disease, 89 AM. J. HUMAN GENETICS 162, 
162 (2011).   
 7 KnomeDiscovery, KNOME, http://knome.com/solutions/knomediscovery/ 
(last visited Oct. 24, 2011). 
 8 David P. Hamilton, The Nitty-Gritty on Knome: How it Works, 
VENTUREBEAT (Nov. 29, 2007), http://venturebeat.com/2007/11/29/the-nitty-gritty-
on-knome-how-it-works/.  Formerly, the FAQs section of the Knome website ex-
plained that consumers will own their genomic information, and that they are under 
no obligation to continue using the company’s services or to maintain their genome 
with Knome. FAQs, KNOME, 
http://web.archive.org/web/20091129101404/http://www.knome.com/about/faqs.html 
(last visited Sept. 17, 2009) (accessed by searching for the URL on Internet Archive 
database). 
 9 DECODEME, http://www.decodeme.com/ (last visited Apr. 12, 2011).  
deCODE is an Icelandic company that endeavored to set up an Icelandic Health Sec-
tor Database (HSD) containing the medical records and genealogical and genetic data 
of all Icelanders. David E. Winickoff, Genome and Nation: Iceland’s Health Sector 
Database and its Legacy, INNOVATIONS, Spring 2006, at 80, 80. 
 10 deCODEme Complete Scan, DECODEME (June 8, 2011), 
http://www.decodeme.com/complete-genetic-scan; deCODEme Cancer Scan, 
DECODEME (Feb. 8, 2010), http://www.decodeme.com/cancer-scan; deCODEme 
Cardio Scan, DECODEME (Feb. 8, 2010), http://www.decodeme.com/cardio-sca 
  11 Conditions We Cover, DECODEME, 
http://www.decodeme.com/conditions-covered (last updated Feb. 18, 2010). 
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ratory in Reykjavik, Iceland, are made available through a genome 
browser tool that gives users access to the variant information on the 
SNPs analyzed in the scan.  The company also offers genetic counsel-
ing through a network of certified genetic counselors, but does not 
require counseling prior to or after using its services.  The company 
states that, as the account owner, the consumer owns the genetic data 
within the deCODE Genetics account, and he or she can choose to 
make the information private or public to all users or only to a list of 
selected “friends.”12  deCODE may also contact users to invite them 
to participate in research studies.13  In fact, the CEO of deCODE, Kari 
Stefansson, has stated that the company has conducted studies involv-
ing more than 10,000 people with the same disease.14  deCODE Ge-
netics also maintains a blog, heralding discoveries by the company 
and announcing the benefits of its tests and products.15   
Although it has not stated its intent to conduct research, one of the 
most recent entries onto the PGT market, Pathway Genomics, has a 
significant social networking component.  Pathway “provides physi-
cians and their patients with genetic testing reports on diet and exer-
cise, drug response, carrier status, and complex health conditions.”16  
Genetic counselors are available for consultation.  Pathway also main-
tains a blog, which addresses genetic news, innovations, and discover-
ies, in addition to company-focused announcements.17 
On its website, the company TruGenetics previously claimed that 
the company would scan 500,000 SNPs for approximately 200 traits 
and illnesses and would provide access to genetic counselors.18  To 
  
 12 deCODEme Privacy Policy, DECODEME, 
http://www.decodeme.com/privacy-policy (last updated June 7, 2011). 
 13 deCODEme Genetic Scan Service Agreement and Informed Consent, 
DECODEME, http://www.decodeme.com/service-agreement (last updated June 7, 
2011).  
 14 Andrew Pollack, Google Co-Founder Backs Vast Parkinson’s Study, N.Y. 
TIMES, Mar. 12, 2009, at B1, B9.   
 15 DECODEYOU, http://decodeyou.com/ (last visited Apr. 12, 2011). 
 16 PATHWAY GENOMICS, http://www.pathway.com/ (last visited Apr. 12, 
2011).  Pathway, which initially sold its test kits as direct-to-consumer products over 
the internet (and at one point intended to sell its kits at Walgreens and CVS stores), 
now markets its services only to physicians.  Turna Ray, FDA on Pathway’s Class I 
Spit Kit Determination: ‘Registration is Not Classification’, PHARMACOGENOMICS 
REP. (Oct. 5, 2011), http://www.genomeweb.com/mdx/fda-pathways-class-i-spit-kit-
determination-registration-not-classification. 
 17 See DNAction Blog, PATHWAY GENOMICS, http://blog.pathway.com/ (last 
visited Apr. 12, 2011).   
 18 TruGenetics Services, TRUGENETICS, 
http://www.trugenetics.com/services/index.htm (last visited Apr. 12, 2011); TruGe-
netics Process, TRUGENETICS, http://www.trugenetics.com/process/ (last visited Apr. 
12, 2011).     
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receive the service, participants would be required to take a personal-
ized risk assessment survey and to store their genetic risk results, sur-
vey results, and other information with TruGenetics.  The company 
also intended to add a social networking element, called TruCommu-
nities.  On its website, TruGenetics disclosed that “[o]ne of the main 
goals of TruGenetics™ is to develop a unique research database for 
conducting genetic studies.”19  In early 2009, TruGenetics declared 
that its genome scanning services would be free to its first 10,000 
customers.20  However, on August 21, 2009, it announced that its 
funding sources had fallen through, and that, for the time being, it 
would not be offering genome scanning services.21  Although the 
company maintains its website, complete with privacy policy and 
terms and conditions, it is not accepting new registrations at this 
time.22 
23andMe is probably the most popular of the PGT companies on 
the market today,23 as much for its approach to genetic testing as its 
relationship to Google (Anne Wojcicki, the co-founder of 23andMe, is 
  
 19 The company stated that it may conduct research, or “may partner with 
another organization, including non-profit and commercial entities, to conduct re-
search.”  Terms & Conditions for Genome Scanning Provided by TruGenetics, 
TRUGENETICS, http://www.trugenetics.com/about/terms.htm (last visited Apr. 12, 
2011) [hereinafter TruGenetics Terms & Conditions].  The Terms and Conditions 
continue: “[y]our decision to use TruGenetics’™ services indicates that you are will-
ing to contribute your questionnaire responses and genetic information to the TruGe-
netics™ research database. This research database will be free of any information that 
can be used to trace this data to you . . . . TruGenetics™ may charge a fee for con-
ducting research using this database.”  Id.  
 20 Money for Nothin’ and Your SNPs for Free?, GENOMEBOY.COM (June 19, 
2009), http://genomeboy.com/2009/06/19/money-for-nothin-and-your-snps-for-free/ 
(linking potential customers to the then-current TruGenetics website: TRUGENETICS 
(June 21, 2009), 
http://web.archive.org/web/20090621083424/http://www.trugenetics.com/? (accessed 
by searching for the URL on Internet Archive database); the TruGenetics website has 
subsequently been changed to reflect the company’s revised policy). 
 21 Dan Vorhaus, 10,000 Free Genome Scans too Good to be Tru?  TruGenet-
ics Announces Fundraising Difficulties, GENOMICS L. REP. (Aug. 21, 2009), 
http://www.genomicslawreport.com/index.php/2009/08/21/free-genome-scans-too-
good-to-be-tru-trugenetics-announces-fundraising-difficulties/. 
 22 Not Accepting New Registrations, TRUGENETICS, 
http://www.trugenetics.com/ (last visited Apr. 12, 2011).   
 23 23ANDME, https://www.23andme.com/ (last visited Apr. 12, 2011); Dan 
Vorhaus, A Thanksgiving Tradition: 23andMe Repackages Product, Raises Prices, 
GENOMICS L. REP. (Nov. 23, 2010), 
http://www.genomicslawreport.com/index.php/2010/11/23/a-thanksgiving-tradition-
23andme-repackages-product-raises-prices/ (discussing repackaging and repricing by 
“23andMe, the most popular provider of direct-to-consumer (DTC) genetic testing 
products.”).  
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married to Sergey Brin, co-founder of Google).24  23andMe’s innova-
tion stems from its coupling of social networking elements with its 
testing service.25   
23andMe posts genetic test results for approximately 100 traits 
and diseases, along with genealogy and ancestry information (the 
“recreational genetics” aspects of the product), on a password pro-
tected website.26  23andMe’s blog, “The Spittoon,” provides educa-
tional posts about genetics, along with a series entitled “SNPwatch,” 
which highlights new research and ties it back to the consumer’s raw 
data.27  23andMe customers are encouraged to become active mem-
bers of the 23andMe community.  One blogger, describing his experi-
ence with 23andMe, explained,  
 
I get to join groups of fellow subscribers with whom I share 
some DNA commonalities, be they connected with health or 
haplotype. For some, these will be support groups of those 
said to share a significant risk of something awful. For others 
it will be a new way to forge genealogical links. New groups 
are formed, almost a parody of the idea of biosocial identity 
that I envisaged . . . .28   
 
  
 24 Katie Hafner, Silicon Valley Wide-Eyed over a Bride, N.Y. TIMES, May 
29, 2007, at C1.  Google, which created a business arm solely focused on venture-
related activities in 2009, “invested in 23andMe and Navigenics, two companies 
offering consumer genetic testing.”  Andrew Pollack, Google’s Venture Arm Invests 
in Biotech Start-Up, N.Y. TIMES (Oct. 1, 2009, 8:37 AM), 
http://bits.blogs.nytimes.com/2009/10/01/googles-venture-arm-invests-in-biotech-
start-up/.  Allegedly, Brin loaned 23andMe $2.6 million in start-up fees that the com-
pany paid back when Google itself became a Series A investor.  David Ewing 
Duncan, The Glamorous Life of Web 2.0 Genetics, CNNMONEY.COM (Sept. 25, 
2009), 
http://money.cnn.com/2009/09/25/technology/23andme_alzheimers_avey.fortune/ind
ex.htm.  Other investors include Genentech and New Enterprise Associates.  Luke 
Timmerman, 23andMe Brings Down the Price of Consumer Genetic Tests, Builds Up 
Relations with Big Pharma, XCONOMY (May 24, 2011), 
http://www.xconomy.com/san-francisco/2011/05/24/23andme-moves-beyond-simple-
consumer-dna-sequencing-sets-sight-on-research/. 
 25 For a thorough description of the social networking aspects of 23andMe, 
see Sandra Soo-Jin Lee & LaVera Crawley, Research 2.0: Social Networking and 
Direct-to-Consumer (DTC) Genomics, AM. J. BIOETHICS, June 2009, at 35, 35. 
 26 23ANDME, https://www.23andme.com/ (last visited Oct. 23, 2011). 
 27 See THE SPITTOON, http://spittoon.23andme.com/ (last visited Apr. 12, 
2011). 
 28 Ian Hacking, Commercial Genome Reading, NAT’L HUMANITIES CTR. 
(Mar. 30, 2009), http://onthehuman.org/2009/03/current-controversies-ian-hacking/. 
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23andMe engaged Informed Medical Decisions, Inc. (In-
formedDNA), a nationwide network of board-certified genetics ex-
perts, to offer independent genetic counseling services to its custom-
ers.29  Linda Avey, co-founder of the company with Wojcicki, has 
spoken out against a “paternalistic” approach to genetic testing, but 
has acknowledged that genetic counseling might be required in certain 
situations.30   
23andMe has devoted its resources to conducting research utiliz-
ing genetic and phenotypic information gathered through its services.  
According to reports, nearly 90 percent of its 125,000 genotyped cus-
tomers have opted to participate in research approved by the com-
pany’s IRB.31  23andMe’s research arm, 23andWe, was the com-
pany’s first attempt to obtain detailed trait information via online sur-
veys of customers.32  The service evolved into more targeted recruit-
ment of specific “research communities” for larger association studies 
for Parkinson’s disease,33 sarcoma,34 and pregnancy.35  The first initia-
tive was launched March 7, 2009, and is an effort to recruit 10,000 
participants for Parkinson’s disease research.  It is funded by Brin, 
who allegedly found out through his wife’s company’s test that he 
was predisposed to the disease.36  Participants receive all 23andMe’s 
services for free and are given access to Parkinson’s disease commu-
nity forums.  As of January 26, 2010, more than 3,500 people with 
Parkinson’s disease had submitted saliva samples for genetic analysis 
  
 29 Press Release, 23andMe, 23andMe Enlists Informed Medical Decisions to 
Make Independent Genetic Counseling Services Available to Customers (June 3, 
2010), available at https://www.23andme.com/about/press/20100603/. 
 30 In September 2009, Avey left 23andMe to start an Alzheimer’s disease 
foundation.  DNA Test Firm Founder to Start Research Foundation, N.Y. TIMES 
(Sept. 4, 2009), available at http://www.nytimes.com/2009/09/05/technology/start-
ups/05bizbriefs-DNATESTFIRMF_BRF.html?_r=1. 
 31 Bruce V. Bigelow, 23andMe Identifies Possible Protective Gene Against 
Parkinson’s Disease, XCONOMY (Oct. 25, 2011), http://www.xconomy.com/san-
diego/2011/10/25/23andme-identifies-possible-protective-gene-against-parkinsons-
disease/. 
 32 Research, 23ANDME, https://www.23andme.com/research/ (last visited 
Apr. 12, 2011). 
 33 23andMe Parkinson’s Community: Strength in Numbers, 23ANDME, 
https://www.23andme.com/pd/ (last visited Apr. 12, 2011); On Our Way to 10,000: 
23andMe Welcomes First Members of Parkinson’s Disease Community, THE 
SPITTOON (Apr. 13, 2009), http://spittoon.23andme.com/2009/04/13/on-our-way-to-
10000-23andme-welcomes-first -members-of-parkinsons-disease-community/. 
 34 23andMe Sarcoma Community: A Patient-Driven Revolution in Sarcoma 
Research, 23ANDME, https://www.23andme.com/sarcoma/ (last visited Aug. 9, 2011). 
 35 Pregnancy Community: See Your Pregnancy in a Whole New Light, 
23ANDME, https://www.23andme.com/pregnancy/ (last visited Apr. 12, 2011). 
 36 See Pollack, supra note 14, at B9. 
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and answered over 30,000 online surveys.37  In addition, more than 
8,000 people without Parkinson’s disease have taken 23andMe’s sur-
veys as control subjects.38  Likewise, individuals who have been diag-
nosed with sarcoma are encouraged to “take an active role in research 
that may benefit you and others living with a similar diagnosis” and to 
“[t]ake action against this disease,” by providing a saliva sample for 
genetic analysis, completing online surveys about their sarcoma expe-
rience and response to treatment, and participating in the “commu-
nity.”39 
In the summer of 2009, 23andMe unveiled Research Revolution, 
where anyone—those with the disease to be studied or healthy volun-
teers who would serve as controls—could participate.40  The princi-
ples of the Research Revolution were as follows: participants who 
purchased the spit test would then “vote” on a predetermined list of 
common diseases on which they would like the company to focus 
research.41  For the first wave of votes, from July 7 through September 
30, 2009, the diseases and traits on which participants could vote in-
  
 37 Nick Eriksson & Lizzie Dorfman, 23andMe Parkinson’s Research Initia-
tive Progress Update, THE SPITTOON (Jan. 26, 2010), 
http://spittoon.23andme.com/2010/01/26/23andme-parkinsons-research-initiative-
progress-update/.  By March 2011, the study had enrolled more than 5,000 partici-
pants with Parkinson’s disease and gathered more than 40,000 data points about their 
experiences with the disease.  An Update on Our Parkinson’s Research Community, 
THE SPITTOON (Mar. 21, 2011), http://spittoon.23andme.com/2011/03/21/an-update-
on-our-parkinsons-research-community/. 
 38 Id. 
 39 23andMe Sarcoma Community: A Patient-Driven Revolution in Sarcoma 
Research, supra note 34.  
 40 Linda Avey, Introducing a Do-It-Yourself Revolution in Disease Research, 
THE SPITTOON (July 7, 2009), http://spittoon.23andme.com/2009/07/07/introducing-a-
do-it-yourself-revolution-in-disease-research/ (linking readers to a now defunct web-
site, The 23andMe Research Revolution, 23ANDME (Jan. 8, 2010), 
http://web.archive.org/web/20100108012414/https://www.23andme.com/researchrevo
lution/ (accessed by searching for the URL on Internet Archive database).  For the 
first phase of Research Revolution, participants could purchase a limited version of its 
testing service at a reduced rate of $99, but 23andMe discontinued offering the serv-
ice at this rate because, as Andro Hsu, then the Manager of Regulatory & Govern-
mental Affairs at 23andMe, stated, “we found that consumer interest is focused on our 
complete product and those users can still pledge to support the program.” Mark 
Henderson, Personal Genomics: 23andMe’s Research Revolution is Over…For Now, 
TIMESONLINE (Jan. 7, 2010), 
http://web.archive.org/web/20100417152440/http://timesonline.typepad.com/science/
2010/01/personal-genomics-23andmes-research-revolution-is-over-for-now.html 
(accessed by searching for the URL on Internet Archive database). 
 41 Jason Kincaid, 23andMe Launches $99 Kit to Spur its ‘Research Revolu-
tion,’ TECHCRUNCH (July 8, 2009), http://techcrunch.com/2009/07/08/23andme-
launches-99-kit-to-spur-its-research-revolution/. 
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cluded epilepsy, migraines, psoriasis, rheumatoid arthritis, and severe 
food allergies.42  Participants then submitted online surveys and ques-
tionnaires related to their “physical traits, health history and behav-
iors.”43  Any diseases that garnered 1,000 or more votes would be-
come the subject of an association study performed by the company’s 
scientists and outside researchers, using the genetic data from the as-
sembled patients and controls.  The company called this collaborative, 
democratizing research: “research of, by and for the people, directed 
and advanced by you.”44  Although Research Revolution itself was 
discontinued due to unprofitability, 23andMe’s customers were in-
formed that they could still participate in research by purchasing the 
company’s full services.45 
In June 2010, a principal investigator at 23andMe, Nicholas 
Eriksson, and his colleagues published the first genome-wide associa-
tion studies (GWAS) on multiple traits ascertained by self-reported 
information provided through the internet.  The article stated that the 
company’s research framework “takes advantage of the interactivity 
of the Web both to gather data and to present genetic information to 
research participants, while taking care to correct for the population 
structure inherent to this study design.”46  Wojcicki, a coauthor, ex-
plained, “[i]n this paper, we confirm that self-reported data from our 
customers has the potential to yield data of comparable quality as data 
  
 42 Id. 
 43 Id. 
 44 Research Revolution—23AndMe, PHARMA STRATEGY BLOG (Aug. 20, 
2009), http://pharmastrategyblog.com/2009/08/research-revolution-23andme.html/ 
(citing the now defunct “Research Revolution” page of the 23andMe website, The 
23andMe Research Revolution, 23ANDME (Jan. 8, 2010), 
http://web.archive.org/web/20100108012414/https://www.23andme.com/researchrevo
lution/ (accessed by searching for the URL on Internet Archive database)). 
 45 Andro Hsu maintained that research will continue to be a fundamental 
aspect of 23andMe’s business model: “Research has always been a fundamental part 
of our platform. 23andMe is focused on providing a great experience for consumers 
while also allowing them to contribute meaningfully to scientific research. We de-
signed our web service to allow customers to participate in research surveys and to be 
engaging enough that they will want to return to our site and continue taking new 
surveys. We’re seeing more and more active involvement of individuals in the man-
agement of their health. 23andMe is part of this shift in focus as far as genetics is 
concerned; but we take individuals a step farther by allowing them to be involved in 
research.”  Henderson, supra note 40.  
 46 Nicholas Eriksson et al., Web-Based, Participant-Driven Studies Yield 
Novel Genetic Associations for Common Traits, 6 PLOS GENETICS 1, 1 (June 2010), 
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000993&representation=PDF. 
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gathered using traditional research methods.”47  The article’s publica-
tion was delayed for almost six months, while the editors of the jour-
nal considered issues related to ethical review, consent, and data ac-
cess.48 
The public sector has responded to the private sector’s move into 
genetic research by offering alternative research initiatives.49  The 
  
 47 Press Release, 23andMe, 23andMe Makes New Discoveries in Genetics 
Using Novel, Web-based, Participant-driven Methods (June 24, 2010), available at  
https://www.23andme.com/about/press/20100624/. 
 48 Greg Gibson & Gregory P. Copenhaver, Consent and Internet-Enabled 
Human Genomics, 6 PLOS GENETICS 1, 1 (June 2010), 
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000965&representation=PDF.  On June 23, 2011, 
23andMe published its second research paper, discovering two novel associations 
with Parkinson’s disease using the largest single Parkinson’s cohort to date, in addi-
tion to replicating 20 previously identified genetic associations with the disease.  See 
Chuong B. Do et al., Web-Based Genome-Wide Association Study Identifies Two 
Novel Loci and a Substantial Genetic Component for Parkinson’s Disease, 7 PLOS 
GENETICS 1, 1 (June 2011), 
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1002141&representation=PDF. 
 49 Some public databases and software for genomic information are already 
being developed or are available to non-profit organizations, academic medical cen-
ters, and other entities devoted to public research.  For example, the International 
HapMap Project was established in 2002 as a partnership of scientists and funding 
agencies from Canada, China, Japan, Nigeria, the United Kingdom and the United 
States to develop a public resource that will help researchers find genes associated 
with human disease and drug responses. About the International HapMap Project, 
INT’L HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last 
visited Apr. 12, 2011). The information produced by the Project will be made freely 
available.  Id.  In phase I, “over 1.1 million SNPs were genotyped in 270 individuals 
from 4 worldwide populations.”  Gudmundur A. Thorisson et al., A User’s Guide to 
the International HapMap Project Web Site, INT’L HAPMAP PROJECT 1 (2005), 
http://snp.cshl.org/downloads/presentations/users_guide_to_hapmap.pdf.  Likewise, 
the 1000 Genomes Project was established in January 2008, as an international effort 
to sequence the genomes of approximately 1,200 people from around the world in 
order to create the most detailed and medically useful picture to date of human ge-
netic variation. Project Overview, 1000 GENOMES PROJECT, 
http://www.1000genomes.org/about (last visited Oct. 23, 2011).  Until recently, the 
collected data were available to the worldwide scientific community through freely 
accessible public databases. See First Data Release: SNP Data Downloads and Ge-
nome Browser Representing Four High Coverage Individuals, 1000 GENOMES 
PROJECT (Dec. 23, 2008), http://www.1000genomes.org/announcements/first-data-
release-snp-data-downloads-and-genome-browser-representing-four-high-covera 
(“The first set of SNP calls representing the preliminary analysis of four genome 
sequences are now available to download through the EBI FTP site and the NCBI 
FTP site.”).  See also About Us, THE RARE GENOMICS INSTITUTE, 
http://www.raregenomics.org/about.php (last visited Oct. 26, 2011).  In December 
2011, the National Human Genome Research Institute announced that would give 
approximately $300 million to three institutes to continue work on the 1000 Genomes 
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Personal Genome Project (PGP) is a public interest, nonprofit re-
sponse to companies like 23andMe and deCODE Genetics, with the 
intention of placing research results in the public domain.50  The PGP 
aims to recruit 100,000 participants to share their genome sequences, 
related health and physical information, and regularly report their ex-
periences.  Participants will also receive online access to their genome 
sequences for their own use.  To enroll in the project, participants 
must take an entrance exam, which covers genetics, regulation, and 
the risks and benefits of genetic technologies.51  The second phase of 
the project has enrolled over 1,000 individuals whose profiles (both 
genetic and phenotypic) are made public on the PGP website.52  Each 
subsequent phase will encompass larger and larger numbers of people.  
The PGP does not provide genetic counseling.   
Despite concerns regarding the inadequacy of DTC genomic tests 
to explain the complexity of genetic information in combination with 
environmental and lifestyle information,53 the questionable clinical 
validity or utility of the tests,54 and the lack of genetic counseling as-
  
Project.  Susan Young, Funds Dedicated to Personalized Genetics: NIH Aims to Push 
Genome-Sequencing into Mainstream Medicine, NATURE NEWS (Dec. 6, 2011), 
http://www.nature.com/news/funds-dedicated-to-personalized-genetics-1.9565. 
 50 See PERSONAL GENOME PROJECT, http://www.personalgenomes.org/ (last 
visited Apr. 12, 2011); see also Newsletter #1, PERSONAL GENOME PROJECT (Apr. 
2009), http://www.personalgenomes.org/newsletter/01.html. 
 51 See Kathleen Page et al., PERSONAL GENOME PROJECT STUDY GUIDE, 
http://www.pgpstudy.org/index.htm (last visited Apr. 12, 2011). 
 52 PGP-1K, PERSONAL GENOME PROJECT, 
http://www.personalgenomes.org/pgp1k.html (last updated Mar. 30, 2011). 
 53 A blogger paid by 23andMe through its pregnancy initiative noted, “[t]he 
geneticist said that over at 23andMe, they were worried that people would just see the 
number and stop reading.  That there’d be all these worried people out there, who 
might need to be a bit careful—but didn’t need to go and start pricking their fingers 
and swearing off chocolate bars, either.”  What? Me Worry? My 23andMe Results, 
23ANDME (Apr. 16, 2009), 
http://agelessbodytimelessmom.wordpress.com/2009/04/16/what-me-worry-my-
23andme-results/.  Most identified risk-marker alleles confer incredibly small risks, 
between 1.1—1.5. Peter Kraft & David J. Hunter, Genetic Risk Prediction—Are We 
There Yet?, 360 NEW ENGL. J. MED. 1701, 1701 (2009). 
 54 See Gail Javitt et al., Developing the Blueprint for a Genetic Testing Reg-
istry, 13 PUB. HEALTH GENOMICS 95, 96 (2009) (“While the number of genetic tests 
continues to grow, publicly accessible information about the analytic and clinical 
validity of such tests is lagging,” and supports the HHS Secretary’s Advisory Com-
mittee on Genetics, Health and Society’s 2008 recommendation to develop a clinical 
registry, for “a more transparent, quality-centered system of oversight that will better 
inform and protect the public.”).  Based on a white paper issued by 23andMe, Navi-
genics, and DeCODE Genetics that described how the companies calculate genetic 
risk, using voluntary industry standards they had developed with the help of the Per-
sonalized Medicine Coalition, Muin Khoury, Director of CDC’s Office of Public 
Health Genomics, stated that companies still diverge on clinical validation issues 
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sociated with DTC genetic testing,55 such tests have been proliferat-
ing.56  Among the most visible are those provided by companies such 
as Navigenics,57 Inherent Health,58 23andMe, deCODE Genetics, 
Knome, and Pathway Genomics, all of whom promise consumers 
knowledge and control over their genetic destinies—and, in many 
cases, the opportunity to participate in, or even drive, genetic re-
search.59   
Although companies like deCODE Genetics and TruGenetics 
have floundered in the recent economic environment, the opportunity 
  
critical to protecting consumer health.  Turna Ray, More Work Needed to Standardize 
Consumer Genomics Offerings, Top US Health Official Says, GENOMEWEB.COM 
(Apr. 15, 2009), http://www.genomeweb.com/dxpgx/more-work-needed-standardize-
consumer-genomics-offerings-top-us-health-official-?page=show; see also Eline 
Bunnik et al., How Attitudes Research Contributes to Overoptimistic Expectations of 
Personal Genome Testing¸ AM. J. BIOETHICS, June 2009, at 23, 24.  Recent studies 
have emphasized the “recreational” nature of genomic testing, focusing on the limited 
predictive capacity of current tests to determine risk. See Kraft & Hunter, supra note 
53, at 1701-03; see also David B. Goldstein, Common Genetic Variation and Human 
Traits, 360 NEW ENGL. J. MED. 1696, 1698 (2009).   
 55 See NAT’L INST. HEALTH, HANDBOOK: HELP ME UNDERSTAND GENETICS, 
111 (Nov. 7, 2011), available at http://ghr.nlm.nih.gov/handbook.pdf. 
 56 For excellent overviews and descriptions regarding genetics, genomics, 
and genetic testing, see Gail H. Javitt et al., Direct-to-Consumer Genetic Tests, Gov-
ernment Oversight, and the First Amendment: What the Government Can (and Can’t) 
Do to Protect the Public’s Health, 57 OKLA. L. REV. 251, 255-56 (2004); Lori An-
drews & Erin Shaughnessy Zuiker, Ethical, Legal, and Social Issues in Genetic Test-
ing for Complex Genetic Disease, 37 VAL. U. L. REV. 793, 798 (2003). 
 57 Founded in 2006, Navigenics’ PGT service does not offer genealogy serv-
ices or a social networking component, but does maintain a blog that gives lifestyle 
tips, provides updates on the company, and discusses genes for which Navigenics 
tests. See NAVIGENICS, http://www.navigenics.com/ (last visited Apr. 12, 2011); The 
Navigator-Navigenics Blog, NAVIGENICS, http://blog.navigenics.com/ (last visited 
Apr. 12, 2011). 
 58 Interleukin Genetics markets a number of “Inherent Health™” genetics 
tests.  About Interleukin Genetics, INTERLEUKIN GENETICS, 
http://www.ilgenetics.com/content/about-interleukin/index.jsp (last visited Apr. 12, 
2011).  Inherent Health genetics tests require a consent form for all consumers of their 
tests, specifically “to document that the person providing their DNA sample to Inher-
ent Health for analysis has done so voluntarily.”  Frequently Asked Questions, 
INHERENT HEALTH, http://www.inherenthealth.com/faq.aspx (last visited Apr. 12, 
2011).  Inherent Health informs its clients that “[y]ou own your genetic data. As a 
result, only you are able to access and download your genetic data and test results.  
Furthermore, you cannot be forced to reveal the results of your genetic test to anyone 
else.”  Id. 
 59 Almost all of these companies state in some form that their products are 
not designed to diagnose, prevent, or treat any condition or disease but are intended 
for educational, informational, and research purposes only.  See, e.g., Consent Docu-
ment, 23ANDME, https://www.23andme.com/about/consent/ (last visited Apr. 12, 
2011).   
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for PGT companies to contribute to and transform the model for re-
search is still very real.  The success or failure of one company cannot 
predict the success or failure of the industry as a whole.  David Alt-
shuler, a medical geneticist at the Massachusetts General Hospital, 
cautioned, “[i]t would be a mistake to draw any connection between 
the medical promise of the human genome and the success of a spe-
cific company and business model.”60 
II. A NEW RESEARCH PARADIGM?: TOWARD A PERSONAL 
 GENOMIC TESTING/SOCIAL NETWORKING HYBRID 
 
As the number of clinical trials in the United States multiply and 
studies require greater numbers of participants, recruitment of re-
search participants becomes increasingly difficult.61  By March 2009, 
there were approximately 50,000 clinical trials underway, of which 80 
percent were delayed at least a month due to low enrollment.62  Con-
sequently, researchers and sponsors of research are seeking access to 
potential research populations in new and different ways.     
At the same time, more and more individuals are seeking health 
information from the internet.  A 2006 Pew Research Center study 
found that 80 percent of internet users in the United States obtain 
health information online,63 a statistic that is likely to increase as on-
line communities and social networking sites continue to multiply.  
And a more recent study found that one in four internet users living 
with high blood pressure, diabetes, heart conditions, lung conditions, 
and cancer have gone online to find others with similar health con-
cerns.64  The PatientsLikeMe Genetics Search Engine65 allows pa-
  
 60 Nicholas Wade, A Genetics Company Fails, Its Research Too Complex, 
N.Y. TIMES, Nov. 18, 2009, at B2. 
 61 Susan Gilbert, Trials and Tribulations, 38 HASTINGS CTR. REP. 14, 14 
(2008); Kenneth A. Getz et al., Assessing the Impact of Protocol Design Changes on 
Clinical Trial Performance, 15 AM. J. THERAPEUTICS 450 (2008).  
 62 Sarah Kliff, Pharma’s Facebook: Research 2.0: How Drug Companies 
are Using Social Networks to Recruit Patients for Clinical Research, DAILY BEAST 
(Mar. 9, 2009), http://www.thedailybeast.com/newsweek/2009/03/10/pharma-s-
facebook.html. 
 63 Susannah Fox, Online Health Search 2006, PEW INTERNET & AMERICAN 
LIFE PROJECT 4 (Oct. 29, 2006), 
http://www.pewinternet.org/~/media//Files/Reports/2006/PIP_Online_Health_2006.p
df.pdf. 
 64 Susannah Fox, Peer-to-Peer Healthcare, PEW INTERNET & AMERICAN LIFE 
PROJECT 2 (Feb. 28, 2011), 
http://pewinternet.org/~/media//Files/Reports/2011/Pew_P2PHealthcare_2011.pdf.  
Very few internet users check the source and date of the information they find.  Fox, 
supra note 63, at iii. 
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tients to “share genetic information and find others like them by the 
gene (and even the specific mutation in that gene) causing their condi-
tion.”66  The co-founder of PatientsLikeMe described the system as 
helping to “realiz[e] the goals of personalized medicine today,”67 and 
the company emphasizes the democratization of data and research 
enabled by its “openness philosophy.”68   
Likewise, pharmaceutical companies have begun to take advan-
tage of the research recruitment opportunities afforded by social net-
working.  Online networking sites like Inspire.com and Patient-
sLikeMe allow users to receive targeted information from pharmaceu-
tical companies who use the site as a recruiting tool for drug studies.69  
In 2008, a partnership between Novartis and PatientsLikeMe led to 
the first effort to recruit research participants for a study (in this case, 
for a multiple sclerosis drug) through a social network.70  In a similar 
effort, Pfizer announced its intention to create an online community to 
increase clinical trial participation, in collaboration with Private Ac-
cess, a health information technology company.71 
  
 65 PATIENTSLIKEME, www.patientslikeme.com (last visited Sept. 17, 2009). 
PatientsLikeMe allow registrants to record, monitor, and share symptoms, severity, 
progression, and treatment (including drug regimens and dosages) on the site.  See id.  
In April 2011, it opened its online community to people with all types of illnesses, 
rather than restricting it to patients with particular chronic diseases. PatientsLikeMe 
Calls All Patients with Any Condition to Join, PATIENTSLIKEME (Apr. 11, 2011), 
http://blog.patientslikeme.com/2011/04/11/patientslikeme-calls-all-patients-with-any-
condition-to-join/. 
 66 Press Release, PatientsLikeMe, PatientsLikeMe Launches Genetics Search 
Engine for ALS Patients (Apr. 22, 2009), available at 
http://www.patientslikeme.com/press/20090422/15-patientslikeme-launches-genetics-
search-engine-for-als-patients. 
 67 David S. Williams III, Our Philosophy, PATIENTSLIKEME, 
http://www.patientslikeme.com/about/openness/ (last visited Sept. 26, 2011) (“Pa-
tientsLikeMe enables you to [a]ffect a sea change in the healthcare system. We be-
lieve that the Internet can democratize patient data and accelerate research like never 
before. Furthermore, we believe data belongs to you the patient to share with other 
patients, caregivers, physicians, researchers, pharmaceutical and medical device com-
panies, and anyone else that can help make patients’ lives better.  Will you add to our 
collective knowledge… and help change the course of healthcare?”). 
 68 David S. Williams III, The Value of Openness, PATIENTSLIKEME (Dec. 13, 
2007, 3:50 PM), http://blog.patientslikeme.com/2007/12/13/the-value-of-openness/. 
 69 Kliff, supra note 62. 
 70 Id. “In May 2008, the site sent out a message to the 8,000 members of 
their multiple-sclerosis community, alerting them to the Novartis trial. From that e-
mail, nearly 1,500 members visited the Novartis website. After recruiting through 
PatientsLikeMe.com, Novartis saw a boost in registrations for the study, although 
they did not track which or how many individuals enrolled because of the cam-
paign—due to patient privacy concerns.” Id. 
 71 The site will “focus on patient privacy rights to connect patients, physi-
cians and researchers with tailored information, tools and technology that will lead to 
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Even before PGT companies entered the fray, commentators had 
already begun considering the pros and cons of online targeted re-
cruitment.72  The proliferation of social networking sites offers re-
searchers and research sponsors the opportunity to access databases of 
personal, genetic, and health-related information.  Crowd-sourcing 
enables pharmaceutical companies to “get easy online access to highly 
engaged populations with specific medical conditions.”73  Online re-
cruitment allows potential participants who might never have heard 
about such studies otherwise, due to geography or other reasons, to 
decide whether enrollment is right for them.  Social networking aids 
recruitment, as participants enlist others from among their connections 
within their network.74     
Although many of the features of research resulting from PGT 
and social networking are new, a number of the underlying issues 
have been discussed at length in the context of biobanks.75  Biobanks 
serve as repositories of biological specimens, which can be analyzed 
to identify gene variations associated with human diseases.  Typically, 
samples are collected during routine clinical and surgical procedures76 
  
more informed decisions about patient care, including clinical trial participation in-
dustry-wide.”  Pfizer and Private Access Announce Plans to Develop Online Commu-
nity to Accelerate Clinical Research, BUSINESS WIRE (Aug. 19, 2009), 
http://www.businesswire.com/news/home/20090819005806/en/Pfizer-Private-
Access-Announce-Plans-Develop-Online. 
 72 In an in-depth piece in August 2009, the New York Times examined the 
practice of collecting patient data and genetic information online to use in recruiting 
patients for clinical trials, conducting research internally or to sell to drug and bio-
technology companies.  Sarah Arnquist, A Research Trove: Patients’ Online Data, 
N.Y. TIMES, Aug. 25, 2009, at D1; see also Editorial, Calling All Patients, 26 
NATURE BIOTECHNOLOGY 953 (2008). 
 73 Kliff, supra note 62. 
 74 Dan O’Connor, Apomediation and the Significance of Online Social Net-
working, AM. J. BIOETHICS, June 2009, at 25, 26. 
 75 For comprehensive considerations of the legal and ethical issues as they 
relate to biobanks, see, e.g., Karen J. Maschke, Biobanks: DNA and Research, in 
FROM BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS CENTER BIOETHICS 
BRIEFING BOOK FOR JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS 11, 12-13 (Mary 
Crowley ed., 2008), available at 
http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/biobank
s%20dna%20and%20research.pdf; The National Bioethics Advisory Commission,  
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance 
(Aug. 1999), available at http://bioethics.georgetown.edu/nbac/hbm.pdf; THE ETHICS 
OF RESEARCH BIOBANKING (Jan Heldge Solbakk, Soren Holm & Bjorn Hofmann, eds., 
2009); ROBERT F. WEIR & ROBERT S. OLICK, THE STORED TISSUE ISSUE: BIOMEDICAL 
RESEARCH, ETHICS, AND LAW IN THE ERA GENOMIC MEDICINE (2004). 
 76 Maschke, supra note 75, at 11 (citing ELISA EISEMAN & SUSANNE B. 
HAGA, HANDBOOK OF HUMAN TISSUE SOURCES: A NATIONAL RESOURCE OF HUMAN 
TISSUE SAMPLES (1999)). 
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or by research initiatives that collect, store, and distribute samples and 
data to researchers.77  Recently, biotech companies have begun to 
build biobanks for the sole purpose of selling or licensing samples and 
data to researchers.78  The circumstances by which samples are col-
lected and obtained may shed new light on the gaps in regulation and 
law as they relate to these issues. 
The move toward online collaboration and the “democratization” 
of data can be seen in the greater context of the transformation of the 
“networked information economy.”79  The “basic change in the mate-
rial conditions of information” due to the increase in electronic infor-
mation sharing has been credited with shifting the role of the partici-
pant and rendering information communication collaborative instead 
of a single-direction endeavor.80   
Ultimately, many of the PGT companies’ business models do not 
focus on profits from the sale of genetic tests, but from gathering the 
genetic and personal data that can be licensed and sold to institutions, 
academic researchers, or drug companies.81  Thus, these companies’ 
mission statements, websites, and advertisements are potentially mis-
leading, convincing PGT consumers that they are either (1) purchas-
ing a recreational service to track ancestry or predisposition to genetic 
conditions, or (2) driving in-house research efforts to find cures and 
benefit society. 
 
  
 77 Id. For example, the author cites the Children’s Hospital of Philadelphia 
project to collect blood samples from more than 100,000 children as part of a genetic 
research initiative to study the most prevalent childhood diseases.   
 78 See, e.g., Anita Huslin, Firm Carves New Model in Biotech Research, 
WASH. POST, Dec. 17, 2007, at D1. 
 79 For example, intellectual property scholar Yochai Benkler is an advocate 
of collaborative research and peer production on the internet and discusses the net-
worked information economy.  See, e.g., Yochai Benkler, Freedom in the Commons: 
Towards a Political Economy of Information, 52 DUKE LAW J. 1245, 1246, 1251, 
1255-56 (2003). 
 80 Id. at 1250 (discussing the decentralizing of the distribution of information 
function). Benkler describes the “commons-based peer production” as “a process by 
which many individuals, whose actions are coordinated neither by managers nor by 
price signals in the market, contribute to a joint effort that effectively produces a unit 
of information or culture.” Id. at 1256. 
 81 David P. Hamilton, 23andMe’s Price Cut: The End of Commercial Personal 
Genomics?, BNET HEALTHCARE (Sept. 9, 2008), 
http://industry.bnet.com/healthcare/1000151/23andmes-price-cut-the-end-of-
commerical-personal-genomics/. However, many companies’ business models focus 
on the money to be made from genetic genealogy and ancestry testing.  Daniel 
MacArthur, Cheap Personal Genomics: The Death-Knell for the Industry?, 
WIRED.COM (Sept. 10, 2008, 11:58 AM), 
http://scienceblogs.com/geneticfuture/2008/09/cheap_personal_genomics_the_de.php 
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III. SHIFTS IN RESEARCH STRUCTURE, TIMING, LOCUS,  AND 
SCOPE  
 
The concerns related to genome-wide research resulting from the 
PGT/social networking hybrid require thoughtful consideration, par-
ticularly in light of transformations in the way that research is done 
and how participants are recruited.  The where, when, who, and how 
of research is shifting, intensified by the fact that all interactions be-
tween research participant and investigator occur online.  Some of 
these shifts are considered below. 
 
A. Shift in the Scope of Use of Genomic and Personal  
Data  
 
Under the typical model for recruitment for clinical research, par-
ticipants are enrolled in studies with an established and IRB-approved 
protocol, and when that study ends, they are no longer research par-
ticipants.  However, once a PGT company has access to one’s ge-
nomic data and the results of surveys revealing physical, behavioral, 
and other personal information, it could ostensibly utilize that data in 
studies ad infinitum.  Thus, potential participants will most likely not 
be signing on for a single, targeted test.  Instead, participants’ genetic 
and phenotypic data might be used for any number of studies, focused 
on any number of genetic traits or illnesses, and overseen and con-
ducted by any number of investigators.  As with biobanked data, the 
use of an individual’s genomic and/or phenotypic information in in-
numerable studies that were not identified at the time of enrollment 
challenges current expectations of how research protocols are defined 
and what it means to participate in research.82     
B. Shift in the Role of the Participant: Patient-Driven 
Research? 
 
Many commentators have applauded the model of participant-
driven research—research that is spurred by and recruited from mem-
bers of online social networks—as “novel and powerful,” exclaiming 
that it will “increasingly come to dominate the genomic research land-
  
 82 Policy for Sharing of Data Obtained in NIH Supported or Conducted Ge-
nome-Wide Association Studies (GWAS), 72 Fed. Reg. 49,290, 49,291 (Aug. 28, 
2007). 
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scape.”83  Scholars may welcome the idea of patient-driven research 
as part of the “commons-based peer production of information [and] 
knowledge . . .,” which permits the “emergence of . . . radically new 
roles that individuals play in the production process.”84  If 23andMe’s 
research agenda is successful in recruiting large numbers of partici-
pants, the initiative could set the stage for progress in terms of re-
cruitment and enrollment.85  Wojcicki described the shift to patient-
driven research as “patient empowerment,” explaining that “[t]wenty 
years ago doctors had tight control over all medical information.  We 
want that power to shift to individuals.”86   
However, it is unclear that customers who contribute genetic and 
personal information for research purposes are “driving” research.  
Under 23andMe’s Research Revolution model, collaboration con-
sisted of a simple “vote” for the disease on which research would be 
focused—a vote purchased with both cash and release of information 
including genetic data, physical traits, health history, and behavior.  
Thus, beyond contribution of genetic and phenotypic information, it is 
questionable that participants would truly be directing research.  They 
did not have a say in the contours of the research or selection of the 
investigators who would conduct the studies.  The power to make all 
these decisions remained in the hands of the research sponsor (in this 
case, 23andMe and its partners).  Significantly, the fact that the re-
search participants may never know how their information is being 
used in a particular study directly conflicts with the notion that par-
ticipants are driving research.  Thus, it is unclear whether this ap-
proach to genetic research is truly democratizing, or is simply an illu-
sion of collective production.  
 
 
  
 83 Daniel MacArthur, The Future of Participant-Driven Genomic Research, 
WIRED.COM (Mar. 12, 2009, 1:10 PM), 
http://www.wired.com/wiredscience/2009/03/The-future-of-participant-driven-
genomic-research. 
 84 Benkler, supra note 79, at 1254-55.   
 85 Daniel MacArthur, 23andMe Launches New Effort to Recruit Patients for 
Disease Gene Studies, WIRED.COM (July 7, 2009, 8:00 PM), 
http://scienceblogs.com/geneticfuture/2009/07/23andme_launches_new_effort_to.php 
(“Modern genomics studies require mind-bogglingly large numbers of samples to 
achieve the power required to find subtle genetic associations, and recruiting those 
numbers of patients is far from easy.”). 
 86 Getting Personal, THE ECONOMIST, Apr. 18, 2009, at 9.  
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C. Shift in the Role of the Participant: Participant 
Self-Organization and Self-Identification  
 
As patients organize into online communities and self-identify for 
participation in research, recruitment and enrollment practices in 
clinical research may begin to transform.87  For example, although 
research arising out of the PGT/social networking hybrid may not be 
as collaborative as the companies claim, the notion of having patients 
self-organize into an online community for a study may still elevate 
the participant to a position of greater authority.88   
Moreover, self-selection may cause the breakdown of the screen-
ing process which has developed over the years to ensure the safety of 
participants as well as the reliability of the resulting data.  With no 
one to screen participants for eligibility, the possibility of selection 
and attrition bias and mis- or over-reporting of symptoms and traits 
will likely increase, undermining the integrity of the data generated 
from such studies.89  In fact, despite deCODE Genetics’ apparent en-
try into the field of research in 2009, its CEO had publicly stated that 
such research may not be useful, because self-reported phenotypes 
are, by and large, unreliable.90  In addition, self-organizing might be 
problematic because, where participants are also providing personal 
information, “[u]ser-generated data is highly variable and poorly con-
trolled.”91 The head of exploratory clinical development at Novartis, 
Trevor Mundel, stated, “[i]t’s something which hasn’t been worked 
through, how [social networks] might worsen the accuracy of adverse-
event reporting.”92  These concerns about accuracy are compounded 
by the fact that, in research arising from the PGT/social networking 
  
 87 Eric S. Lander, the Founding Director of the Broad Institute of MIT and 
Harvard, has stated that the idea of having patients “self-organize” into an online 
community for a study, rather than be recruited, is “a Googley thing to do.”  Pollack, 
supra note 14, at B9. 
 88 It has been noted that investigators may not appreciate the “intrusion” of 
patients or patient advocates into their research. See Do-it-Yourself Science, 449 
NATURE 755, 756 (2007). 
 89 For example, as patients in the same study might communicate with and 
reveal significant information to one another on social networking sites, they could 
possibly deduce who is taking the test drug versus placebos.  Kliff, supra note 62; see 
also Arnquist, supra note 72, at D6.   
 90 Mark Henderson, Cashing in on Your Genes: Will Personal DNA Testing 
Soon be Big Business and Will Our Genetic Data be Safe?, TIMES (London) (Jan. 7, 
2010), available at 
http://www.timesonline.co.uk/tol/news/science/eureka/article6975520.ece?token=null
&offset=0&page=1. 
 91 Calling All Patients, supra note 72. 
 92 Kliff, supra note 62.   
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hybrid, research participants and investigators never meet, which may 
further transform how participants view their own role in the research 
and hinder investigators’ ability to gauge the veracity of research sub-
jects and the quality of the data.   
 
D. Expectations of Care and Intensifying the Thera-
peutic Misconception 
 
 The marketing and promotion for initiatives like 23andMe’s re-
search agenda might mislead participants to think that, even if they 
may not benefit financially from their participation, they will benefit 
medically and therapeutically.93  The promises of collaboration and 
democratization could exacerbate an already very real problem—the 
therapeutic misconception—that arises when research participants do 
not understand the distinction between treatment and research.94  This 
is particularly relevant where companies have two primary and seem-
ingly unrelated purposes: providing genetic and ancestry information 
to customers and developing research databases.95  Currently, 
23andMe, Pathway Genomics, TruGenetics, and even the PGP offer, 
or plan to offer, both genetic screening services and the opportunity to 
participate in genome-wide research.  Critics of DTC genetic testing 
already point out that these companies may be overpromising the 
therapeutic advantages of these tests.  When the therapeutic miscon-
ception is coupled with the promises of research—which is not in-
tended to provide clinical benefits—participants may become further 
confused or misled as to the benefits of participation.   
This confusion may intensify due to the lack of mandatory genetic 
counseling for participants.  Only some PGT companies offer any 
genetic counseling services.96  For many participants, there is no one 
to dispel the therapeutic misconception, particularly in the absence of 
  
 93 In the non-research context, most, if not all, PGT companies disclose the 
fact that customers should not expect medical benefits for their testing services, and 
that test results are no substitute for physician-provided medical care.  However, in 
the research setting, the lines easily become more blurred. 
 94 See Paul S. Appelbaum et al., Therapeutic Misconception in Clinical Re-
search: Frequency and Risk Factors, 26 IRB: ETHICS & HUM. RES., Mar.-Apr. 2004, 
at 1, 1; Paul S. Appelbaum et al., Correction and Clarification, 26 IRB: ETHICS & 
HUM. RES., Sept.-Oct. 2004, at 18, 18. 
 95 For example, TruGenetics declares that its services will “help you explore 
your genes.” TruGenetics Process, supra note 18.  On a separate page, TruGenetics 
also states that “[o]ne of the main goals of TruGenetics is to develop a unique re-
search database for conducting genetic studies.” TruGenetics Terms & Conditions, 
supra note 19.  
 96 As of this writing, these companies include Navigenics, deCODE Genet-
ics, Pathway Genomics, and 23andMe. 
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a physician-intermediary or investigator to explain test results, de-
scribe research protocols, and answer questions. 
IV.  LEGAL, ETHICAL, AND REGULATORY CONSIDERATIONS 
 FOR RESEARCH 
 
These shifts in who, when, how, and where give rise to a number 
of practical issues, and a thorough consideration of these shifts reveals 
gaps in the current regulatory and legal regime for protecting partici-
pants in research studies.  In particular, the areas of concern include 
the informed consent process during recruitment and enrollment, lack 
of IRB oversight, and confused expectations related to therapeutic 
benefits.  The regulatory checks and controls applied to other types of 
research may not be comprehensive or targeted enough to address the 
problems that arise out of social networking-based genetic research.   
The well-known 2003 lawsuit between the Havasupai Tribe in 
Arizona and the Arizona Board of Regents and the University of Ari-
zona and Arizona State University highlights some of the ethical is-
sues related to the collection and use of DNA samples, even without 
the use of social networking technologies.  Members of the tribe al-
leged that the defendants had used blood samples submitted solely for 
diabetes research for genetic research into schizophrenia, inbreeding, 
and ancient population migration.97  Among a number of publications 
and research projects that relied on the misused data were four doc-
toral dissertations and a number of academic papers, many of which 
were completely unrelated to the research to which the Havasupai had 
agreed.98  In April 2010, the University’s Board of Regents settled, 
agreeing to pay $700,000 to members of the tribe, return the blood 
samples obtained between 1990 and 1994, and provide other forms of 
assistance.99   
Many of the ethical and legal considerations concerning the col-
lection and use of genetic and phenotypic data—particularly those 
related to informed consent—become even more pronounced with 
  
 97 Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063, 1066 (Ariz. Ct. 
App. 2008).  After the Arizona Court of Appeals ruled that the tribe could sue the 
Arizona Board of Regents and the Universities, the Arizona Supreme Court agreed to 
hear the appeal of one of the researchers. Havasupai Tribe v. Ariz. Bd. of Re-
gents, No. CV-09-007-PR, 2009 Ariz. LEXIS 82 (Apr. 20, 2009). 
 98 Of particular concern to the Havasupai Tribe was the fact that many of the 
papers related to theories about ancient human population migrations from Asia to 
North America, which is contrary to their belief that the tribe originated in the Grand 
Canyon. Havasupai Tribe, 201 P.3d at 1067. 
 99 Amy Harmon, Tribe Wins Fight to Limit Research of its DNA, N.Y. 
TIMES, Apr. 22, 2010, at A1. 
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research conducted under genome-wide initiatives using online serv-
ices.  Some investigators have highlighted the implications of publish-
ing and sharing aggregate genomic data, particularly considering that, 
despite aggregation, it may be possible to identify (or re-identify) an 
individual’s genomic data within a large pool of data.100  The authors 
of one article concluded that, “the policies and practices guiding ge-
nomic data sharing should continue to evolve in order to promote 
quality science, minimize duplicative research and merit the ongoing 
trust of the research subjects who consent to participate in scientific 
studies.”101 
 
A. Current Human Subjects Recruitment and En-
rollment Law as it Applies to Social Networking-
Based Genetic Research 
 
Commentators have noted confusion about when the federal rules 
and regulations governing research with humans apply to research 
with biospecimens and the associated data.102  Concerns about in-
formed consent for participants in research arising from PGT data-
bases are particularly acute, since empirical literature indicates that 
most people are willing to grant consent for genetic studies.103  But, 
investigators are often not able—or not required—to obtain consent 
for use of collected or stored samples.     
The Common Rule, the law governing human subject research in 
the United States for research conducted or supported by any of eight-
een federal departments or agencies, regulates informed consent.104  
  
 100 Nils Homer et al., Resolving Individuals Contributing Trace Amounts of 
DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays, 
PLOS GENETICS 1, 2, 7, 9 (Aug. 2008), 
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000167&representation=PDF; Kevin B. Jacobs et al., A 
New Statistic and Its Power to Infer Membership is a Genome-Wide Association 
Study Using Genotype Frequencies, 41 NATURE GENETICS 1253, 1253 (2009); Sriram 
Sankararaman et al., Genomic Privacy and Limits of Individual Detection in a Pool, 
41 NATURE GENETICS 965, 965 (2009). 
 101 Jacobs, supra note 100, at 1257. 
 102 Maschke, supra note 75, at 11, 12-13 (“Some rules conflict with each 
other, and there are differences in how the rules define ‘research,’ ‘human subjects,’ 
and ‘identifiable’ personal information.  How these terms are defined determines 
whether IRBs must approve biospecimen research, and whether individuals must give 
consent for use of their stored biospecimens or their identifiable genetic and other 
medical information.”). 
 103 David Wendler, One Time General Consent for Research on Biological 
Samples, 332 BRIT. MED. J. 544, 547 (2006).  
 104 See 45 C.F.R. § 46 (2010). 
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The Common Rule defines research as “a systematic investigation, 
including research development, testing and evaluation, designed to 
develop or contribute to generalizable knowledge.”105  It requires that 
investigators explain to participants the purposes of their research, the 
mechanisms to ensure confidentiality, the existence of IRB oversight 
of the research protocol and consent process, and the risks of the re-
search.106  In terms of risk, there may be little individual physical risk 
in social networking-related genetic research because of the lack of 
clinical implications for the participant.  However, individual informa-
tional risks and group harms are a very real possibility.107  Population-
based genomic research could lead to further stigmatization or dis-
crimination against racial or ethnic groups.   
Whether research utilizing biospecimens collected as part of a 
PGT service constitutes human subjects research under the Common 
Rule is unsettled.108  Although, in some cases, even filling out a basic 
paper survey falls under the umbrella of research, survey procedures 
are exempt from the Common Rule, unless the information is directly 
or indirectly identifiable and any disclosure outside the research could 
reasonably place the subjects at risk of liability or be damaging to the 
subject’s financial standing, employability, or reputation.109  However, 
contribution of biological samples and genetic information goes be-
yond simple survey procedures, and the revelation of personal behav-
ioral and physical information as well as family history could easily 
affect employability and reputation.  Guidance issued by the Office of 
Human Research Protections (OHRP) suggests that studies using 
samples that were not collected for the purpose of research “through 
an interaction or intervention with living individuals,” and for which 
“the investigator(s) cannot readily ascertain the identity of the indi-
vidual(s) to whom the coded private information or specimens per-
tain,” do not constitute human subjects research.110  However, com-
  
 105 Id. § 46.102(d). 
 106 Id. § 46.116. 
 107 Laura M. Beskow et al., Informed Consent for Population-Based Research 
Involving Genetics, 286 JAMA 2315, 2318 (2001); Marc D. Schwartz et al., Consent 
to the Use of Stored DNA for Genetics Research: A Survey of Attitudes in the Jewish 
Population, 98 AM. J. MED. GENETICS 336, 336 (2001) (“[P]articipants were signifi-
cantly less willing to participate in research that examined stereotypical or potentially 
stigmatizing traits as opposed to research that examined medical or mental ill-
nesses.”).  
 108 See Christian M. Simon et al., Active Choice but Not Too Active: Public 
Perspectives on Biobank Consent Models, 13 GENETICS MEDICINE 821, 821 (2011). 
 109 45 C.F.R. § 46.101(b)(2). 
 110 OHRP, Guidance on Research Involving Coded Private Information or 
Biological Specimens (Oct. 16, 2008), available at 
http://www.hhs.gov/ohrp/policy/cdebiol.html; see also Human Subjects Research 
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mentators have noted that it is generally recognized that informed 
consent is necessary before an individual contributes biological sam-
ples for research.111   
Recently proposed revisions by the Department of Health and 
Human Services (HHS) and the Office of Science and Technology 
Policy would do much to clarify the extent and scope of the Common 
Rule for research conducted using biospecimens.112  The Advance 
Notice of Proposed Rulemaking (ANPRM) recommends the most 
substantive changes to the Common Rule in approximately twenty 
years, in response to the transforming and expanding research enter-
prise.  Generally, it proposes a series of modifications in order to in-
crease protections of research participants while reducing burden, 
delay, and ambiguity for investigators.113  First, the ANPRM would 
expand the scope of the Common Rule’s authority, applying the pro-
tections contained therein to all studies, regardless of funding source, 
that are conducted at United States institutions that receive some fed-
eral funding for human subjects research from a Common Rule de-
partment or agency.114  Notably, it would extend the informed consent 
requirements for research on biospecimens and require that an indi-
vidual give consent, in writing, for research use of their biospeci-
mens.115  However, the ANPRM envisions that consent may be one-
time and general, rather than study specific, and would cover all fu-
ture research.116  At donation, individuals may choose not to sign a 
  
Protections: Enhancing Protections for Research Subjects and Reducing Burden, 
Delay, and Ambiguity for Investigators, 76 Fed. Reg. 44,512, 44,519 (July 26, 2011) 
(acknowledging that “the current rules… allow research without consent when a 
biospecimen is used for research under conditions where the researcher does not 
possess information that would allow them to identify the person whose biospecimen 
is being studied.”). 
 111 Wendler, supra note 103, at 547. 
 112 See Human Subjects Research Projections: Enhancing Protections for 
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 
Fed. Reg. at 44,512.  The ANPRM was issued, in part, in response to allegations that 
“uncertainty about the regulations on biospecimens has impeded research.”  Ezekiel 
Emanuel & Jerry Menikoff, Reforming the Regulations Governing Research with 
Human Subjects, 365 NEW ENGL. J. MED. 1145, 1148 (2011). 
 113 See Human Subjects Research Projections: Enhancing Protections for 
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 
Fed. Reg. at 44,512.   
 114 Id. at 44,528. 
 115 Id. at 44,515. 
 116 In a comment addressing the ANPRM, the Secretary’s Advisory Commit-
tee on Human Research Protections (SACHRP) advised against general consent for 
all future uses of biospecimens as a way to protect participants from harm.  See Letter 
from Barbara E. Bierer, Chair, Secretary’s Advisory Committee on Human Research 
Protections, to the Honorable Kathleen Sebelius, Secretary of Health and Human 
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standardized general consent form granting open-ended consent; in 
such cases, they may prohibit the use of their biospecimens for future 
research.  Further, the proposed modifications would eliminate the 
distinction between research on biospecimens collected for research 
and nonresearch purposes.117  This last point directly implicates re-
search conducted on biospecimens collected through social network-
ing PGT sites, as often these samples are not collected for the purpose 
of research, although the companies may then seek to use and share 
the data for that reason. 
The Health Insurance Portability and Accountability Act (HIPAA) 
restricts how certain identifiable health information may be used and 
disclosed, including for research.118  Genetic information is protected 
to some extent under HIPAA, after being amended by the Genetic 
Information Nondiscrimination Act (GINA) to include “genetic in-
formation” as “health information.”119  However, 
anonymized biological material is not considered protected health 
information under HIPAA.120  Because of the ease of re-identification 
  
Services 43-45 (Oct. 2011), 
http://www.dfhcc.harvard.edu/fileadmin/DFHCC_Admin/Clinical_Trials/OPRS/Form
s_Instructions/ANPRM/SACHRP_ANPRM_comment.pdf (“[N]o researcher would 
have a reliable way of predicting, for purposes of informed consent adequate under 
the Common Rule, the full range of specific future uses of data and biospecimens that 
would be widely acceptable to American society in 25, 50, or 100 years; such a gen-
eral future consent therefore could not be sufficient under the Common Rule to obvi-
ate the necessity, prior to a researcher’s undertaking a later specific study, of applying 
to an IRB for waiver of informed consent.”).   
 117 Human Subjects Research Projections: Enhancing Protections for Re-
search Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 
Fed. Reg. at 44,527. 
 118 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 
104-191, 110 Stat. 1936, 2023.  The HIPAA rules apply only to health plans, health-
care clearinghouses, and certain health-care providers, and not all investigators are 
part of a covered entity. See Human Subjects Research Projections: Enhancing Pro-
tections for Research Subjects and Reducing Burden, Delay, and Ambiguity for In-
vestigators, 76 Fed. Reg. at 44,514.  However, it has been argued that HIPAA is inef-
fective in protecting personally identifiable information (PII).  See Arvind Narayanan 
& Vitaly Shmatikov, Myths and Fallacies of “Personally Identifiable Information,” 
COMM. ACM, June 2010, at 24, 26 (“PII has no meaning even in the context of the 
HIPAA Privacy Rule.”). 
 119 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 
§1180, 122 Stat. 881, 904. 
 120 In July 2010, the HHS proposed two new provisions to HIPAA intended to 
streamline the process for obtaining informed consent for clinical trial participation 
and authorization for use of protected patient data and biological materials.  Modifica-
tions to the HIPAA Privacy, Security, and Enforcement Rules Under the HITECH 
Act; Proposed Rule, 75 Fed. Reg. 40,868 (proposed July 14, 2010) (to be codified at 
45 C.F.R. pt. 164). The first provision allows for compound authorizations which 
would allow use of a single informed consent document for both enrollment in a 
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(and the “impossibility” of full de-identification) of biospecimens, the 
July 2011 ANPRM recommends adopting the HIPAA standards for 
purposes of the Common Rule regarding what constitutes individually 
identifiable information and de-identified information, and categoriz-
ing all research involving the collection of biospecimens as well as 
storage and secondary analysis of existing biospecimens as research 
involving identifiable information.121  
To the extent they do not receive federal funds for research, com-
panies like 23andMe are not covered by the Common Rule.  If they 
intend to bring a product to market, however, PGT companies may be 
subject to the Food and Drug Administration (FDA) human subject 
protection requirements, which are similar to those enumerated in the 
Common Rule.122  FDA regulations govern clinical studies submitted 
in marketing applications for new drugs and biological products and 
marketing applications and reclassification petitions for medical de-
vices.  Under FDA rules, there are eight basic elements of informed 
consent, including an explanation of the purposes of the research and 
the expected duration of participation, a description of the procedures 
to be followed, identification of any experimental procedures, a de-
  
clinical trial and future research use of patient data and human tissue.  Id. at 40,892.  
Under the proposed rule, HIPAA-covered entities could combine both conditioned 
and unconditioned authorizations, as long as the document clearly states that the 
individual may opt in to the unconditioned research activities.  Id.  The second provi-
sion would modify the HHS rule that authorization for future use of protected health 
information in research be study-specific.  Id. at 40,893, 40,894.  Moreover, in order 
to remain consistent with the Common Rule, SACHRP and the Institute of Medicine 
(IOM) have both recommended that HHS allow researchers to seek consent for future 
research if there is enough description of possible future uses in the document to 
allow for informed consent. Medical Research Law & Policy Report, HIPAA Pro-
poses Rule Change to Streamline Informed Consent, Authorization for Research, 9 
MRLR 441 (July 21, 2010). 
 121 See Human Subjects Research Projections: Enhancing Protections for 
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 
Fed. Reg. at 44,525.  The ANPRM recognizes that advances in “genetic and informa-
tion technolog[y] [have made] complete de-identification of biospecimens impossible 
and re-identification of sensitive health data easier.”  See also Narayanan & Shmati-
kov, supra note 118, at 26 (“Unfortunately, advances in the art and science of re-
identification, increasing economic incentives for potential attackers, and ready avail-
ability of personal information about millions of people (for example, in online social 
networks) are rapidly rendering [de-identification] obsolete.”).  However, SACHRP 
does not endorse the assertion that biospecimens are inherently identifiable.  Letter 
from Barbara E. Bierer to the Honorable Kathleen Sebelius, supra note 116 at 53. 
 122 See 21 C.F.R. §§ 50, 56, 312, 812 (2011); see Comparison of FDA and 
HHS Human Subject Protection Regulations, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/Education
alMaterials/ucm112910.htm (last updated Mar. 10, 2009). 
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scription of foreseeable risk, appropriate alternative procedures or 
courses of treatment, and a statement of voluntariness.123   
For example, the recruitment of research participants on social 
networking sites such as PatientsLikeMe, like in the case of Novartis’ 
2008 study for a multiple sclerosis drug, would be subject to FDA 
regulations.124  The FDA considers direct advertising for study par-
ticipants to be the start of the informed consent and recruit-
ment/enrollment process, explaining that “[a]dvertisements should be 
reviewed and approved by the IRB as part of the package for initial 
review.”125  As noted above, however, in the studies proposed by 
companies like 23andMe, individuals may have been recruited, and 
have agreed to participate in hypothetical research, without any prior 
knowledge of how their genetic and phenotypic information will be 
used or who will be doing the research.  Thus, they may already be 
“participating” in research (having submitted a biological sample and 
disclosed personal information and family history) before a protocol 
has been put in place.  In those cases, there is no one to screen poten-
tial participants, no one responsible for the informed consent process, 
and personal data could presumably be used repeatedly in a number of 
different studies and scenarios.  
Moreover, certain studies may not be subject to FDA oversight, as 
the agency’s authority only covers trials relied upon to determine and 
establish a product’s safety and efficacy126—not, for example, studies 
necessary for obtaining patent protections, Phase IV trials, or gener-
ally, where the company and/or sponsor are seeking to identify ge-
netic predispositions to traits or illnesses but are not seeking to create 
  
 123 21 C.F.R. § 50.25. 
 124 A Safety and Efficacy Study of ELND002 in Patients with Relapsing Forms 
of Multiple Sclerosis, PATIENTSLIKEME, 
http://www.patientslikeme.com/clinical_trials/NCT01144351-MS-SPMS-RRMS-
Relapsing-Forms-of-Secondary-Progressive-Multiple-Sclerosis-SPMS-or-Relapsing-
Remitting-Multiple-Sclerosis-RRMS (last visited Sept. 17, 2009).  
 125 Recruiting Study Subjects—Information Sheet, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/RegulatoryInformation/Guidances/ucm126428.htm (last 
updated Oct. 18, 2010).  FDA guidance makes clear that direct online advertising for 
potential clinical research participants is not per se objectionable: “IRB review and 
approval of listings of clinical trials on the internet would provide no additional safe-
guard and is not required when the system format limits the information provided to 
basic trial information, such as: the title; purpose of the study; protocol summary; 
basic eligibility criteria; study site location(s); and how to contact the site for further 
information. Examples of clinical trial listing services that do not require prospective 
IRB approval include the National Cancer Institute’s cancer clinical trial listing 
(PDQ) and the government-sponsored AIDS Clinical Trials Information Service 
(ACTIS).”  Id. 
 126 Id. § 54.2(e). 
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a drug or device that would require FDA approval.127  Such gaps in 
the regulatory scheme are troubling.128 
There is little relevant case law regarding informed consent and 
the donation of genetic data for research.  It might be argued that 
sponsors of research have a duty to disclose the possibility that a cus-
tomer’s genetic information will be used for various and unpredictable 
research purposes which would lead to the inurement of the company.  
However, a federal district court declined to extend the duty of in-
formed consent to cover disclosure of an investigator’s financial inter-
ests in studies in which the participants’ biological samples were 
used.129   
B. Ensuring Informed Consent in Social Networking-
Based Genetic Research 
 
In light of diverging and incomplete regulations, there is obvious 
disagreement regarding the method and structure of informed consent 
for genome-wide research, particularly research that originates from 
data collected via social networking by PGT companies.  As noted 
above, the investigators, nature, purpose, and methods of future re-
search may not be known or identified at the time samples are col-
lected.130  Even assuming that it is enough that participants sign an 
informed consent document, the issue of how far the consent can and 
should go still exists.  To what may participants consent?  Can they 
consent solely to research related to a specific illness?  If so, should 
there be an opt-out option for certain types of research?  Can partici-
pants give blanket consent covering all research utilizing their per-
sonal and genetic information?  Or must participants be approached 
each time a new study is initiated?  Empirical research suggests that, 
when participating in genetic studies, many people want to be asked to 
  
 127 See U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-06-402, DRUG SAFETY: 
IMPROVEMENT NEEDED IN FDA’S POSTMARKET DECISION-MAKING AND OVERSIGHT 
PROCESS 6 (2006), available at http://www.gao.gov/new.items/d06402.pdf. 
 128 See Letter from Barbara E. Bierer to the Honorable Kathleen Sebelius, 
supra note 116 at 36 (providing a useful list of areas and types of research that are not 
currently subject to federal regulations that protect participants of research). 
 129 Greenberg v. Miami Children’s Hosp. Research Inst., 264 F. Supp. 2d 
1064, 1070 (S.D. Fla. 2003) (tissue and fluid donors accused the physician-
investigator of failing to inform the donors that the hospital stood to benefit finan-
cially from the research on Caravan disease). 
 130 See id. at 1069. For a thorough review of proposals for informed consent 
in data collection in biobanking, see also Elena Slavaterra et al., Banking Together: A 
Unified Model of Informed Consent for Biobanking, 9 EMBO REP. 307, 307-10 
(2008). 
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be enrolled for each study or type of study.131  However, re-contacting 
a large number of sample donors for consent may be impractical or 
even impossible.132   
Commentators have noted the divergent informed consent prac-
tices in the United States for research conducted on biological sam-
ples.133  Research reveals evidence that IRBs vary in their consent 
form requirements for genetic research.134  A survey of thirty studies 
involving biospecimens determined that one-time general consent, 
with the requirement that an ethics committee reviews and approves 
future projects, is the “best option,” as it reflects the preference of 
most individuals.135  Research has also demonstrated that potential 
participants would prefer a prospective opt-in consent approach, 
rather than an opt-out process.136  Additionally, due to concerns about 
genomic privacy for those participating in research, commentators 
have advocated an open-consent framework.137  At the very least, the 
  
 131 Darren Shickle, The Consent Problem with DNA Biobanks, 37 STUD. HIST. 
& PHIL. BIOLOGICAL & BIOMEDICAL SCI. 503, 513 (2006). 
 132 See Paul S. Appelbaum, Professor, Columbia Univ., Informed Consent: 
Recent Developments in Legal and Ethical Requirements for Data Collection and 
Use, available at 
http://www7.nationalacademies.org/cpop/Appelbaum%20Presentation.pdf (last vis-
ited Sept. 17, 2009) (citing Shickle, supra note 131).  
 133 Leslie E. Wolf & Bernard Lo, Untapped Potential: IRB Guidance for the 
Ethical Research Use of Stored Biological Samples, IRB: ETHICS & HUM. RES., July-
Aug. 2004, at 1, 1-2.  
 134 See Mary T. White & Jennifer Gamm, Informed Consent for Research on 
Stored Blood and Tissue Samples: A Survey of Institutional Review Board Practices, 
9 ACCOUNTABILITY RES. 1 (2002).  The authors found greater attention to human 
subjects protection corresponding to the location of the IRB, the number of protocols 
evaluated each year, whether the IRB included a member with ethical expertise in 
genetics, and whether the IRB used both the IRB Guidebook and the National Bioeth-
ics Advisory Commission (NBAC) Report on Research Involving Human Biological 
Materials in its deliberations.  Id. at 2, 13-15. 
 135 Wendler, supra note 103, at 546.  The author notes that although one-time 
general consent “does not allow people to control the projects for which their samples 
are used, there is no reason to think that they want to make such decisions.” Id.  The 
author recommends six specific elements for the consent form and process: “request 
to obtain samples for future research; risks, if any; absence of direct benefits; infor-
mation, if any, to be provided by individuals; reliance on ethics committees to review 
and approve future research provided it finds the research is ethical and poses no 
greater than minimal risk; and solicitation of individual questions.”  Id. at 546-47.  
See also Simon, supra note 108, at 826 (finding that, in consenting to future research, 
participants prefer broad, research-unspecific consent over categorical and study 
specific consent models).  
 136 Simon, supra note 108, at 826. 
 137 See, e.g., Jeantine E. Lunshof et al., From Genetic Privacy to Open Con-
sent, 9 NATURE REV. GENETICS 406, 409 (2008). 
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consent process, including consent forms, should address the possibil-
ity of data sharing.138   
There is little evidence that PGT companies have devoted ade-
quate time or energy to concerns regarding informed consent, and 
PGT companies seeking to collect and use individuals’ genetic and 
phenotypic data have been reluctant to explicitly describe how con-
sent to research would be ensured in all cases.  Most of these compa-
nies’ policies focus on the implications of testing and participating in 
the recreational aspects of their products, without considering, sepa-
rately and thoroughly, the need for an informed consent process for 
research conducted as a result of an individual’s participation in their 
services.  In fact, it has been noted that the information provided in 
the PGT companies’ documents “focus[es] on privacy protections, the 
corporate intent to give information but no diagnosis or health as-
sessment, and the fact that data sharing is the responsibility of the 
individual,” rather than focusing on the risks associated with the col-
lection of data or the types of studies to be undertaken.139  For exam-
ple, users of deCODE Genetics’ products are not required to sign a 
consent form, but are informed on the website that the “deCODEme 
genetic scan is for informational purposes only; it is not a medical 
test, and it is by no means a substitute for professional medical advice, 
genetic counseling, diagnosis, or treatment.”140  23andMe does ad-
dress informed consent for research,141 albeit deficiently, by requiring 
that prior to having their sample processed, users must read and ac-
knowledge an online “Consent and Legal Agreement” which discloses 
some, but not all, elements of informed consent (e.g., although it 
states that the company may enter into partnerships with both for-
profit and nonprofit organizations for the purpose of scientific re-
search, it does not provide a description of the research).142  The Per-
  
 138 See Susan Wallace et al., Consent and Population Genomics: The Crea-
tion of Generic Tools, IRB: ETHICS & HUMAN RES., Mar. 2009, at 15, 16. 
 139 Karin Esposito & Kenneth Goodman, Genethics 2.0: Phenotypes, Geno-
types, and the Challenge of Databases Generated by Personal Genome Testing, AM. 
J. BIOETHICS, July 2009, at 19, 20. 
 140 Frequently Asked Questions, DECODEME, http://www.decodeme.com/faq 
(last visited Apr. 12, 2011). 
 141 According to 23andMe, customers must agree to be involved in its 
23andMe Research initiative.  The “Consent and Legal Agreement” states that 
23andMe will only provide individual level data to external researchers upon individ-
ual consent from each customer.  Consent Document, supra note 59.  In fact, a bill 
introduced in California, supported by 23andMe, would (among other things) require 
companies to obtain informed consent before using individuals’ de-identified genetic 
data for research purposes. S.B 482, 2009-10 Reg. Sess. (Cal. 2009). 
 142 Consent Document, supra note 59.  Shortly before publication, 23andMe 
revised its privacy statement, with the support of a privacy-verifying consultant, 
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sonal Genome Project’s two-step informed consent process involves 
detailed informed consent documents which are periodically updated; 
they include contact information for the primary investigator and oth-
ers and more closely represent the framework for informed consent 
envisioned by the Common Rule.143  Prospective participants must 
read, review, and electronically sign two different consent forms: (1) a 
“mini-consent” for eligibility screening procedures; and (2) the full 
consent for enrollment and ongoing participation.144    
Even if PGT companies’ forms and online policies made compre-
hensive disclosures as to the consequences of participation in re-
search, the companies’ approaches to informed consent would still be 
insufficient.  Informed consent is best understood as a process, rather 
than a one-time occurrence where a simple form is read and signed, 
that obligates investigators to ensure that potential research partici-
pants appreciate and understand the risks, benefits, and alternatives to 
participating in research.  Because informed consent often requires a 
meeting with a medical provider or someone involved in the research 
to explain the risks and implications of participation and answer ques-
  
TrustE.  Privacy Highlights Page, 23ANDME, 
https://www.23andme.com/legal/privacy/ (last visited Dec. 9, 2011); Summary of 
Changes to the 23andMe Privacy Statement, 23ANDME, 
https://www.23andme.com/you/faqwin/privacychanges/ (last visited Dec. 9, 2011).  
Of the substantive changes to the general privacy policy—as it applies to the collec-
tion and handling of personal information for recreational purposes, site use statistics, 
and customer testimonials—the company added one provision related to research, 
which allows third-party research consultants to do on-site research at 23andMe fa-
cilities, utilizing data from participants who have consented to 23andWe Research.  
See also Kashmir Hill, Privacy Policy Changes Should be Crystal Clear, Especially 
When Your Genes are Involved, FORBES.COM (Dec. 7, 2011, 12:05 PM), 
http://www.forbes.com/sites/kashmirhill/2011/12/07/privacy-policy-changes-should-
be-crystal-clear-especially-when-your-genetic-info-is-involved/. 
 143 Current Consent Forms, PERSONAL GENOME PROJECT, 
http://www.personalgenomes.org/consent/ (last visited Oct. 23, 2011).   
 144 Participation Overview, PERSONAL GENOME PROJECT, 
http://www.personalgenomes.org/participate.html (last updated Mar. 3, 2011); see 
also Mini Consent Form, PERSONAL GENOME PROJECT, 
http://www.personalgenomes.org/consent/PGP_MiniConsent_Approved_02222011.p
df (last visited Oct. 23, 2011).  The mini consent form discloses a principal investiga-
tor, and describes the purpose broadly, “to explore ways to connect human genetic 
information with human trait information (i.e., human DNA sequence, medical infor-
mation, tissue samples and physical traits) so that such data may be used for hypothe-
sis-generating research and other scientific, clinical and commercial development 
efforts worldwide.” Id.  Cf. Full Consent Form, PERSONAL GENOME PROJECT, 
http://www.personalgenomes.org/consent/PGP_Consent_Approved_02222011.pdf 
(last visited Oct. 23, 2011). 
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tions,145 only requiring participants to sign an online consent form 
before contributing to research may not be enough to meet the ele-
ments of the FDA regulations or the Common Rule.  Most companies 
have not identified if and how they intend to follow up with partici-
pants (although TruGenetics has stated its intent to eventually share its 
discoveries),146 how participants can ask questions or express con-
cerns during the course of a study, or whether or when participants 
may withdraw from the research if they change their mind.  Further 
consideration is needed to determine how best to disclose risks and 
benefits to customers so that they understand the implications and 
breadth of potential participation in research. 
C. IRB Oversight of Social Networking-Based    
Research: An “Unfortunate Loophole” 
 
Where studies are subject to FDA regulations and the Common 
Rule, they must be approved by an IRB to assure that appropriate 
steps are taken to protect the rights and welfare of participants.  How-
ever, many of the PGT companies have not publically identified an 
IRB for approval of their research protocols.  Nor may companies be 
eager for IRB oversight; a bill supported by 23andMe that was intro-
duced in the California legislature in April 2009 would explicitly not 
require companies to obtain IRB approval before conducting research 
using genetic data.147  In cases where there is no IRB to oversee the 
informed consent process, there is little guarantee that research par-
ticipants’ rights will be protected.     
In March 2009, OHRP released its GINA Guidance148 to clarify 
how GINA will affect genetic research that is conducted or supported 
  
 145 Institutional Review Boards Frequently Asked Questions — Information 
Sheet, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm  (last updated 
Aug. 9, 2011) (“The entire informed consent process involves giving a subject ade-
quate information concerning the study, providing adequate opportunity for the sub-
ject to consider all options, responding to the subject’s questions, ensuring that the 
subject has comprehended this information, obtaining the subject’s voluntary agree-
ment to participate and, continuing to provide information as the subject or situation 
requires.”). 
 146 TruGenetics Terms & Conditions, supra note 19. 
 147 See S.B 482, 2009-10 Reg. Sess. (Cal. 2009). 
 148 GINA prohibits discrimination in health coverage and employment based 
on genetic information, with implications for disclosure and informed consent.  Office 
for Human Research Prot., Guidance on the Genetic Information Nondiscrimination 
Act: Implications for Investigators and Institutional Review Boards, DEP’T HEALTH & 
HUMAN SERVS. 1-2 (Mar. 24, 2009), http://www.hhs.gov/ohrp/policy/gina.pdf.  GINA 
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by HHS.149  The Guidance provides nonbinding recommendations to 
researchers, emphasizing that investigators and IRBs should disclose 
reasonably foreseeable risks related to genetic research and not over-
state the protections provided by GINA.150  Investigators and IRBs 
must continue to vigilantly monitor how risks are described for ge-
netic research, because GINA does not apply to life insurance, disabil-
ity insurance, and long-term care insurance.  For these types of insur-
ance, providers may deny coverage or increase premiums based on 
known genetic predispositions.  The Guidance recommends specific 
language for investigators and IRBs to include in informed consent 
documents.  Further, the Guidance recommends that IRBs overseeing 
genetic research should also consider the provisions of GINA when 
assessing whether such research satisfies the criteria required for ap-
proval, keeping in mind that risks to subjects are minimized and rea-
sonable in relation to anticipated benefits, and there are adequate pro-
visions to protect the privacy of subjects and maintain the confidenti-
ality of data.151   
When 23andMe sought publication of its GWAS on multiple traits 
using self-reported data via the internet, the journal PLoS Genetics 
delayed publication to consider the company’s lack of IRB review.152  
23andMe asserted that its study was exempted from review because it 
was not “human subjects research.”  In the same issue in which the 
final article appears, the journal’s editors stated that, “[o]n the face of 
it, this seems preposterous, but on further review, this decision fol-
lows not uncommon practices by most scientists and institutional re-
view boards, both academic and commercial, and is based on a guid-
ance statement from [OHRP].”153  The editors called this an “unfortu-
  
went into effect for health insurance companies in May 2009 and for employers in 
November 2009.  Id. 
 149 GINA includes a “research exception” to the prohibition against requesting 
that an individual undergo a genetic test, which allows “a group health plan, or a 
health insurance issuer offering health insurance coverage in connection with a group 
health plan” to “request, but not require, and that a participant or beneficiary undergo 
a genetic test if” certain conditions are met.  These conditions include that the re-
search comply with the Common Rule, participation is voluntary, that the government 
is notified in writing of the research.  Genetic Information Nondiscrimination Act of 
2008, Pub. L. No. 110-233, §1180, 122 Stat. 881, 904. 
 150 Office for Human Research Prot., Guidance on the Genetic Information 
Nondiscrimination Act: Implications for Investigators and Institutional Review 
Boards, DEP’T HEALTH & HUMAN SERVS. 5 (Mar. 24, 2009), 
http://www.hhs.gov/ohrp/policy/gina.pdf. 
 151 Id. 
 152 Gibson & Copenhaver, supra note 48. 
 153 Id. (stating the two criteria that qualify research as human subject research: 
(1) “will the investigators obtain the data through intervention or interaction with the 
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nate loophole.”154  The journal further required that the authors ad-
dress their concerns about the consent process, and in response, 
23andMe has fully engaged a formal IRB.  In June 2010, 23andMe 
announced that it had received IRB approval for its research protocol 
and an accompanying revised consent document for its research in-
tended for publication, although the company explicitly disavowed 
being required to do so.155  In its announcement, the statement ex-
plained, “[b]ecause the 23andMe protocol excludes individual identi-
fying information (e.g. name, email address, user ID, Password, pay-
ment information, etc.) and our analysts do not interact directly with 
customers during data collection, our research technically does 
not require IRB review.”156 
V. OWNERSHIP/INTELLECTUAL PROPERTY CONCERNS 
 
Some of the policies listed on PGT companies’ websites are am-
biguous as to ownership of the biospecimens or data collected for 
research.157  For example, formerly, Pathway’s disclosures simply 
stated, “[y]our DNA and results belongs to you and no one else.”158  
Then, in what might have been a confusing switch for the consumer, 
the company asserted that it may use certain information that does not 
disclose the customer’s identity to conduct scientific and medical re-
search, in collaboration with nonprofit or commercial organizations.159   
  
participants,” and (2) “will the identity of the subject be readily ascertained by the 
investigator or associated with the information.”) (citing Office for Human Research 
Prots., Guidance on Research Involving Coded Private Information or Biological 
Specimens, DEP’T HEALTH & HUMAN SERVS. 2 (Oct. 16, 2008), 
http://www.hhs.gov/ohrp/policy/cdebiol.pdf).  
 154 Id. at 2.  
 155 23andMe Improves Research Consent Process, THE SPITTOON (June 24, 
2010), http://spittoon.23andme.com/2010/06/24/23andme-improves-research-consent-
process/. 
 156 Id. (alteration in original). 
 157 The PGP, which has a different focus than the for-profit DTC genetic 
testing companies, clearly states, “[n]either you nor your heirs will gain financially 
from any discoveries, whether or not of a commercial nature, made using the informa-
tion that you provide.”  Mini Consent Form, supra note 144.  
 158 Pascal Borry et al., Preconceptional Genetic Carrier Testing: Direct-to-
Consumers: The Appropriate Use of Existing Resources, 26 HUM. REPROD. 972, 975 
(2011) (linking readers to a since-modified website, DNA Security, PATHWAY 
GENOMICS, 
http://web.archive.org/web/20100515174056/http://www.pathway.com/more_info/dn
a_security (last visited Sept. 17, 2009) (accessed by searching for the URL on Internet 
Archive database)). 
 159 Privacy Policy, PATHWAY GENOMICS, 
http://web.archive.org/web/20090328011950/http://www.pathway.com/more_info/pri
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Generally, institutions have successfully claimed ownership of 
biospecimens.  In the 1990 case Moore v. Regents of the University of 
California, the Supreme Court of California held that a patient with 
hairy cell leukemia had a cause of action against his physician based 
on a breach of fiduciary duty because the physician failed to disclose 
his intent to use portions of the plaintiff’s spleen in research for which 
the physician hoped to benefit financially.  However, the court even-
  
vacy_policy (last updated Mar. 20, 2009) (“We may provide your Genetic Informa-
tion and Survey-Based Information, unlinked from your name and Account Informa-
tion, to research collaborators to conduct Pathway Genomics-authorized scientific 
research and development.  You cannot opt-out from this research.  We also may pass 
on to you a research collaborator’s request that you volunteer additional information 
or participate in a study.  No name or Account Information is shared with a research 
collaborator without your express consent.”) (emphasis added) (accessed by searching 
for the URL on Internet Archive database).  Later, the policy explained, “Pathway 
Genomics believes in furthering responsible scientific and medical research to im-
prove our understanding of genetics and to assist physicians and other health-care 
professionals to provide better health care. Collaborations between Pathway Genom-
ics and non-profit or commercial research organizations will be guided by a research 
advisory committee established by Pathway Genomics. Any research collaborator will 
first need to obtain permission from an appropriate Institutional Review Board.”  
Privacy Policy, PATHWAY GENOMICS, 
http://web.archive.org/web/20100405082115/http://www.pathway.com/more_info/pri
vacy_policy (last updated Dec. 21, 2009) (accessed by searching for the URL on 
Internet Archive database). This policy has subsequently been changed to what they 
refer to as an opt-in system, and now reads, “Pathway may want to work with other 
entities and organizations to conduct scientific research and other legitimate secon-
dary purposes using the DNA obtained from your specimen. However none of your 
personal information will be shared for any secondary purpose outside the immediate 
control of Pathway, unless you expressly opt-in to authorize this….  We also may 
pass on to you a research collaborator’s request that you volunteer additional informa-
tion or participate in a study. No name or Account Information is shared with a re-
search collaborator without your express consent and the research collaborator agree-
ing to comply with all appropriate privacy and information security laws and regula-
tions to protect such personal information.” Privacy Policy, PATHWAY GENOMICS, 
https://www.pathway.com/more_info/privacy_policy (last updated Oct. 22, 2010).  
Similarly, 23andMe’s privacy policy states, “[i]f you do not give consent for your 
Genetic and Self-Reported Information to be used in 23andWe Research, we may still 
use your Genetic and/or Self-Reported Information for R&D purposes… which may 
include disclosure of Aggregated Genetic and Self-Reported Information to third-
party non-profit and/or commercial research partners who will not publish that infor-
mation in a peer-reviewed scientific journal.”  Privacy Highlights Page, supra note 
142.  However, it continues, “[e]xcept as otherwise set forth herein, we will never 
release your individual-level Genetic and/or Self-Reported Information to a third 
party without asking for and receiving your explicit consent to do so, unless required 
by law.”  Id. 
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tually found that donors do not have an ownership interest in their 
cells after the cells have been removed from their bodies.160   
In 2008, in Washington University v. Catalona, the Eighth Circuit 
upheld the lower court’s decision that tissue and serum samples do-
nated to Washington University could continue to be used by the insti-
tution for cancer research, despite the donors’ wishes to transfer own-
ership of the samples to another research institution.  The Court of 
Appeals stated that the “pivotal inquiry in this dispute” was “whether 
individuals who make an informed decision to contribute their bio-
logical materials voluntarily to a particular research institution for the 
purpose of medical research retain an ownership interest allowing the 
individuals to direct or authorize the transfer of such materials to a 
third party.”161  The Court held that “[u]nder the facts of this case, the 
answer is no.”162    
It is not unprecedented for companies to prevent others from 
studying or testing a gene for which they hold a patent.  An ongoing 
lawsuit against Myriad Genetics has highlighted the controversy sur-
rounding the U.S. Patent & Trademark Office (USPTO)’s permissive 
attitude toward gene sequence patents.  In March 2010, the Southern 
District of New York held that isolated human genes were unpaten-
table subject matter, and invalidated Myriad’s patent claims relating to 
the BRCA1 and BRCA2 genes.163  In July 2011, the Court of Appeals 
partially reversed the lower court’s decision, holding that isolated 
DNA is patentable because it is markedly different from the DNA as it 
exists within the body and is therefore not simply a product of na-
  
 160 Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 493 (Cal. 1990). 
However, Moore has questionable application, because the relationship between the 
testing companies and the participants in these cases is not a therapeutic one, and 
because these PGT companies disclose to participants that they will not benefit finan-
cially. Id. at 483.  However, to the extent that PGT companies are not explicit in their 
intent, it implicates the court’s belief that Moore’s physician’s behavior was particu-
larly egregious, as he actively misled Moore by telling him that the research team was 
“engaged in strictly academic and purely scientific medical research” and “there was 
no commercial or financial value to his Blood and Bodily Substances.” Id. at 486.  
See also Greenberg v. Miami Children’s Hosp. Research Inst., 264 F. Supp. 2d 1064, 
1073 (S.D. Fla. 2003) (tissue and fluid donors alleged that hospital had fraudulently 
concealed that it: (1) would economically benefit from the research; (2) would patent 
the Canavan gene mutation; and (3) would license the testing under the patent).   
 161 Wash. Univ. v. Catalona, 490 F.3d 667, 673 (8th Cir. 2007). See also Lori 
Andrews, Who Owns Your Body? A Patient’s Perspective on Washington University 
v. Catalona, J. L. MED. & ETHICS 398, 298 (2006).   
162  Wash. Univ., 409 F.3d at 673. 
 163 Whether genetic tests and diagnostic tools are patentable is at issue in the 
ACLU suit against the PTO and Myriad Genetics for Myriad’s screening tests for the 
breast cancer genes, BRCA1 and BRCA2.  See Ass’n for Molecular Pathology v. 
USPTO, 702 F. Supp. 2d 181, 222 (S.D.N.Y. 2010). 
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ture.164  The Court upheld, however, the invalidity of the patent claim 
over the analytic process for examining and comparing genes to iden-
tify the BRCA mutations because it involved “patent-ineligible ab-
stract[] mental steps.”165  The case is being appealed. 
It is foreseeable that contributors of genetic and biological data 
might assert a property right in applications or products that arise out 
of research.  However, patient-driven research does not correlate to 
patient-owned results and products.  Throughout the process of col-
lecting data, developing diagnostic tools and tests, and designing 
treatments, applications, pharmaceuticals, or biologics, a number of 
products may become ripe for patenting, licensing, and marketing.166  
Based on the fine print found on PGT websites, it is often clear that 
the participant/consumer will not financially gain from his or her par-
ticipation.  
Despite claims of democratization and collaboration, both public 
and private companies assert that they themselves will retain and ex-
ercise the right to any property interest created by the research.  These 
companies may, however, negotiate ownership and IP rights with their 
commercial partners, or deal the rights away to other third parties.   
However, recent USPTO actions have indicated that collaborating 
in genetic research may constitute inventorship.167  Initiatives such as 
the PGP will likely spur nonscientist collaborators to ask the USPTO 
to consider granting them joint inventorship.  The partnership of so-
cial networking and genetic testing projects will certainly lead to a 
demand to expand the concept of joint inventorship.  Even to the ex-
tent that participants do not have a legal right to the intellectual prop-
erty arising out of research, participants may still expect or seek ac-
cess to tests developed from the results of their contribution for a dis-
count. 
 
 
 
 
  
 164 Ass’n for Molecular Pathology v. USPTO, 653 F.3d 1329, 1333-34 (Fed. 
Cir. 2011). 165 Id. at 1334. 
 166 For a thorough consideration of the issues related specifically to gene 
patenting, an area itself rife with issues, see Lori B. Andrews & Jordan Paradise, 
Gene Patents: The Need for Bioethics Scrutiny and Legal Change, 5 YALE J. HEALTH 
POL’Y L. & ETHICS 403, 403-04 (2005). 
 167 See Jordan Paradise, Patient Advocacy Group Collaboration in Genetic 
Research and the Scope of Joint Inventorship Under U.S. Patent Law, 3 INT’L J. 
INTELL. PROP. MGMT. 97, 100, 104 (2009) (stating that the USPTO named a non-
science advocate as a co-inventor on a patent for a disease gene). 
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CONCLUSION 
 
As the story of Lorenzo Odone exemplifies, research driven by 
patients’ preferences and needs is not unique to genetic research aris-
ing out of social networking.  Recent history is rife with individual 
initiatives, foundations, and companies dedicated to spurring research 
and finding cures.  In 2003, the daughter of Hugh Rienhof, the foun-
der of DNA Sciences and an advisor to biotech companies, was born 
with undiagnosed congenital defects.168  He had her genes sequenced 
and shared information about her conditions and portions of her ge-
netic information on the internet.  The founder of PatientsLikeMe 
started the online company after his brother, Stephen Heywood, was 
diagnosed with Lou Gehrig’s disease (both brothers had previously 
founded ALS TDF, a nonprofit biotechnology company and ALS 
research center).  Stephen spent the last three years of his life on an 
experimental drug developed by ALS TDF.169   
Initiatives such as the PGP are poised to compete with efforts by 
for-profit companies such as 23andMe.170  Such competition is remi-
  
 168 Brandan Maher, Personal Genomics: His Daughter’s DNA, 449 NATURE 
772, 773 (2007). 
 169 Stephen Heywood, 37, Dies; Master-Builder/Architect Subject of the 2006 
Major Motion Picture So Much So Fast, PATIENTSLIKEME (Nov. 30, 2006), 
http://www.patientslikeme.com/press/20061130/1-stephen-heywood-37-dies-
masterbuilder-architect-subject-of-the-2006-major-motion-picture-so-much-so-
fast?disease_tag=hiv. 
 170 The PGP is by no means the only non-profit initiative focused on using 
genomics and social networking to identify diseases and pursue treatments.  The Rare 
Genomics Institute (RGI)’s initiative is perhaps the most patient-driven of its kind.  
RGI, a nonprofit organization founded in 2011 that aims to “empower[] patient com-
munities to accelerate research by helping fund and creating personalized research 
projects based on individuals with rare diseases,” provides three interrelated services: 
(1) a “micro-funding website,” an “online fundraising platform and social network 
that helps patient community raise funds”; (2) a researcher network, which provides 
access to genomics researchers who will sequence and analyze the patients’ informa-
tion; and (3) a clinical network, which connects “patients with clinicians and genetic 
counselors who will help interpret and translate the individualized research findings.” 
About Us, THE RARE GENOMICS INSTITUTE, http://www.raregenomics.org/about.php 
(last visited Oct. 26, 2011). Thus, a patient diagnosed with a rare disease that is con-
sidered a good candidate for sequencing-based research is invited to create an online 
profile, tell his or her story, and upload pictures in an effort to raise funds to support 
the research. For Patients, THE RARE GENOMICS INSTITUTE, 
http://www.raregenomics.org/patients.php (last visited Oct. 26, 2011).  RGI will then 
coordinate the use of these community-raised funds and anonymized rare disease 
patient genomes in research.  Researchers who conduct research utilizing data pro-
vided by RGI may publish results, together with the organization.  By using a crowd-
funding approach to raise money for whole genome sequencing and analysis in chil-
dren with rare or orphan genetic diseases, the organization hopes to contribute to a 
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niscent of the “race” between Craig Venter and the Human Genome 
Project (HGP), where privately-funded researchers (who are subject to 
different and, often less, regulation) forced a publicly-funded institu-
tion to compete, resulting in increased effectiveness and productivity 
on both sides.171  In an ideal world, the contest to recruit volunteers to 
contribute genetic and other personal information would encourage 
research and competition to create diagnostics and treatments that will 
benefit society.172   
  
better understanding of diseases and the development of new treatments.  Currently, 
the organization’s website does not contain any information regarding privacy or 
consent, but does state that “RGI will ensure that patient information is kept in the 
strictest confidence according to government regulations.”  It continues, “[s]equences 
will only be made available to the research community once they have been com-
pletely anonymized.” For Patients, THE RARE GENOMICS INSTITUTE, 
http://www.raregenomics.org/patients.php (last visited Oct. 26, 2011). Further, RGI’s 
website contains the following disclaimer: “[a]ll the genome sequencing projects are 
for research informational purposes only and are subject to change. No medical medi-
cal [sic] advice, diagnosis or treatment are provided.” For Donors, THE RARE 
GENOMICS INSTITUTE, http://www.raregenomics.org/donors.php (last visited Oct. 26, 
2011). 
 171 See Getting Personal: The Promise of Cheap Genome Sequencing, 
ECONOMIST, Apr. 18, 2009, at 9, 10.  The HGP sequenced the genome for $4 billion, 
while Venter did it for $100 million.  Id. at 10. 
 172 In a novel approach to genetic research and social networking, openSNP, a 
non-profit, open-source project founded in September 2011, seeks to allow customers 
of direct-to-customer genetic tests—currently, deCODE Genetics and 23andMe—to 
publish their raw data test results and phenotypes, characteristics, and traits, find 
others with similar genetic variations, and search primary literature on their variations 
and “help scientists to find new associations.”  OPENSNP, http://opensnp.org/ (last 
visited Oct. 28, 2011).  Participants make their full genotypic raw data available on-
line, which may be accessed via a mass download-function “to enable everybody 
to perform crowd-sourced association studies,” thereby “making science more open 
and accessible.” For Scientists, OPENSNP, http://opensnp.org/ (last visited Oct. 28, 
2011); About, OPENSNP, http://opensnp.wordpress.com/about (last visited Oct. 28, 
2011); 5 Days After Launch—Time for Some More Information, OPENSNP (Oct. 3, 
2011), http://opensnp.wordpress.com/2011/10/03/5-days-after-launch-
%E2%80%93%C2%A0time-for-some-more-information/.  Future features to be 
added include social media efforts and support for Family Tree DNA, another service 
that provides DTC-testing.  The organization describes 23andMe’s policy of not 
sharing its datasets with other researchers outside of 23andMe and their collaborators, 
and explains its decision to make such information public: “[w]hile there may be 
many valid reasons not to publish those datasets, we feel that research projects all 
over the world and science in general would benefit from such a rich source of linked, 
genetic data that is freely available.” Welcome to openSNP, OPENSNP (Sept. 26, 
2011), http://opensnp.wordpress.com/2011/09/26/welcome-to-opensnp/.  openSNP’s 
“disclaimer” describes the “possible risks and side-effects that can occur by making… 
genetical and medical information available on this platform,” including challenges to 
privacy (“[a]lthough you can upload your data using a pseudonym, there is no way to 
anonymously submit data”), confidentiality, and the potential for genetic discrimina-
tion. Disclaimer, OPENSNP, http://opensnp.org/disclaimer (last visited Oct. 28, 2011).  
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However, PGT companies that utilize online social networking 
technologies are ushering in a new model for human subjects re-
search, one which our current laws, regulations, institutions, and IRBs 
may not be prepared to handle.  PGT companies, despite good inten-
tions, may not be in the best position to protect the needs, desires, and 
rights of customers who choose to participate in research initiatives.  
These companies often blur the line between the recreational and the 
clinical, and individuals may not be fully informed of the risks and 
benefits of participating in research advanced by PGT companies.  In 
fact, one of the most challenging aspects of the hybrid of PGT and 
social networking is the fact that customers may become research 
participants without full knowledge or understanding of the transfor-
mation of their roles.  In order to ensure the appropriate use of PGT 
sites for recruiting purposes, transparency in partnerships between 
pharmaceutical companies and PGT providers is necessary, so that 
users understand the nature of the relationships and how they fit in.   
A greater focus on regulation of the PGT/social networking hy-
brid model for research is essential.  A deliberate evaluation of the 
application of existing laws and a consideration of new ones is needed 
in order to find a balance between efficient research using personal 
and genetic information with the long-term interests and values of 
individuals.  Our first approach should be a reconsideration of how 
our current consent model applies to social networking-based genetic 
research.  Recent publications of GWAS by PGT companies have 
intensified the need for a consistent and standardized informed con-
sent process.  Obtaining more adequate, honest, and complete consent 
from participants would be most effective at the time of initial contri-
bution of information, although in some circumstances, re-consent 
may be required.  Further, clarifying (and if necessary, extending, 
regardless of funding source) the reach of the Common Rule to 
crowd-sourced genetic research would help to ensure the protection of 
all participants.   
 
